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Summary 
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Summary 
 
Mast cells exert important functions in innate and adaptive immunity and are 
therefore strategically located at inner and outer body surfaces, such as skin, 
gastrointestinal tract and blood vessels. Once mast cells are activated, they 
release a broad array of prestored or newly synthesized mediators, including a 
series of cytokines and chemokines. Recent studies showed that mast cells 
also infiltrate many types of solid cancers and hematologic malignancies. Here, 
mast cell products can participate in creating a microenvironment that either 
promotes or inhibits tumor growth. However, the role of mast cells in tumor 
biology is still controversial and underlying mechanisms remain largely 
undefined. In the present study, we show for the first time that mast cell 
numbers are significantly increased in skin biopsies from patients with primary 
cutaneous lymphoma. Mast cell infiltration is most prominent in the periphery, at 
lymphoma rims. Also, degranulation of mast cells is significantly increased. 
Interestingly, patients with advanced stages of the disease show higher mast 
cell counts than stable patients. Similarly, numbers of mast cells correlate with 
disease progression. In addition, mast cell numbers correlate with the density of 
microvessels. Supernatant of cultured mast cells induces in vitro production of 
cytokines and proliferation in primary cutaneous lymphoma cells. To further 
elucidate the contribution of mast cells to tumor biology, we use new transgenic 
mouse models of inducible or constitutive selective deficiency of connective 
tissue mast cells and show that growth of subcutaneously injected tumors and 
chemically induced carcinogenesis is significantly decreased in mast cell-
deficient mice. Taken together, these experiments demonstrate that mast cells 
play a tumor-promoting role in human primary cutaneous lymphoma and 
different murine tumor models. Moreover, our data provide a rationale for 
exploiting tumor-associated mast cells as prognostic marker and therapeutic 
target in primary cutaneous lymphoma and other tumors. 
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Zusammenfassung 
 
Mastzellen üben entscheidende Funktionen in der angeborenen und adaptiven 
Immunantwort aus. Sie kommen deshalb in besonders großer Zahl an inneren 
und äußeren Körperoberflächen vor, wie z.B. in der Haut, im Magen-Darm-Trakt 
und in der Nähe von Blutgefäßen. Wenn Mastzellen aktiviert werden, 
sezernieren sie viele verschiedene gespeicherte oder neu synthetisierte 
Mediatoren, z.B. zahlreiche Zytokine und Chemokine. Infiltrate aus Mastzellen 
finden sich auch in vielen soliden Tumoren und hämatologischen Neoplasien. 
Die Produkte der Mastzellen können hier eine Umgebung schaffen, die 
entweder das Tumorwachstum fördert oder hemmt. Die genaue Funktion der 
Mastzellen in der Tumorbiologie wird jedoch noch kontrovers diskutiert und die 
zugrunde liegenden Mechanismen sind weitgehend unbekannt. Die vorliegende 
Arbeit zeigt erstmals, dass Mastzellen auch in Hautbiopsien von Patienten mit 
primären kutanen Lymphomen signifikant vermehrt sind. Die Infiltrate aus 
Mastzellen finden sich vor allem im Randbereich der Lymphome. Die 
Degranulation von Mastzellen ist ebenfalls deutlich gesteigert. 
Interessanterweise zeigen Patienten mit fortgeschrittenen Krankheitsstadien 
höhere Mastzellzahlen als stabile Patienten. Vergleichbar korreliert die 
Mastzellzahl auch mit dem Fortschreiten der Krankheit. Weiterhin korreliert die 
Zahl der Mastzellen mit der Dichte der Gefäße. In vitro induziert der Überstand 
von kultivierten Mastzellen die Produktion von Zytokinen und Proliferation von 
primären kutanen Lymphomzellen. Um den Beitrag von Mastzellen zur 
Tumorbiologie weiter aufzuklären, haben wir neue transgene Mausmodelle 
verwendet, die eine induzierbare oder konstitutive Defizienz von 
Bindegewebsmastzellen aufweisen, und zeigen, dass das Wachstum von 
subkutan injizierten Tumoren und chemisch induzierten Papillomen in diesen 
Tieren signifikant erniedrigt ist. Zusammenfassend belegen diese Experimente, 
dass Mastzellen eine Tumor-fördernde Funktion bei primären kutanen 
Lymphomen und verschiedenen murinen Tumormodellen besitzen. Die Daten 
liefern zudem die Basis für weitere Untersuchungen zur Nutzung von Tumor-
assoziierten Mastzellen als prognostischer Marker und therapeutisches Target 
in primären kutanen Lymphomen und anderen Tumoren. 
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Abbreviations 
 
%   percentage 
°   degree 
µg   mikrogram 
µl   mikroliter 
µM   mikromolar 
A   tumor area 
AD   atopic dermatitis 
Ang   angiopoietin 
BAC   bacterial artificial chromosome 
BCL   primary cutaneous diffuse large B-cell lymphoma 
BMMC   bone marrow-derived mast cells 
bp   base pairs 
C   celsius 
Ca I   calcium ionophore 
CBA   cytometric bead array 
CBCL   cutaneous B-cell lymphoma 
CCL2   MCP-1 
CCL5   RANTES 
CD   cluster of differentiation 
CD30+ALCL                  CD30 positive primary cutaneous anaplastic large  
cell lymphoma 
cDNA   complementary DNA 
CFBCL   primary cutaneous follicle center lymphoma  
COX   cyclooxygenase 
CSF   colony stimulating factor 
CTCL   cutaneous T-cell lymphoma 
CTMC   connective tissue mast cell 
Ctrl   control 
CXCL10  IP-10 
CXCL8   IL-8 
CXCL9   MIG 
DC   dendritic cell 
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DMBA   7,12-Dimethylbenz(a)anthracene 
DMEM   dulbecco´s modified eagle medium 
DMSO   dimethyl sulfoxide 
DNA   deoxyribonucleic acid 
dNTP   deoxynucleoside triphosphate 
DT   diphtheria toxin 
DTR   diphtheria toxin receptor 
ED   extensively degranulated 
EDTA   ethylenediaminetetraacetic acid 
ELISA   enzyme-linked immunosorbent assay 
EORTC  European Organization of Research and  
Treatment of Cancer 
FACS   fluorescence-activated cell sorting 
FBS   fetal bovine serum 
FGF   fibroblast growth factor 
FMF   folliculotropic mycosis fungoides 
Fwd   forward 
g   gram 
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
G-CSF   granulocyte-colony stimulating factor 
GM-CSF  granulocyte-macrophage colony-stimulating factor 
h   hours 
H&E   hematoxylin/eosin 
HBSS   hank´s balanced salt solution 
Hetero   heterozygous 
Homo   homozygous 
HPLC   high-performance liquid chromatography 
HSC   hematopoietic stem cell 
i.p.   intraperitoneal 
IFN   interferon 
Ig   immunoglobulin 
IL   interleukin 
IMDM   iscove´s modified dulbecco´s medium 
ISCL   International Society of Cutaneous Lymphoma 
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kb   kilo-base pair 
LP   lymphomatoid papulosis 
LT   leukotriene 
M   molar 
MC   mast cell 
MCP   mast cell progenitor 
Mcpt5   mast cell protease-5 
MD   moderately degranulated 
MDSC   myeloid-derived suppressor cells 
MF   mycosis fungoides 
mill   million 
min   minute 
MIP   macrophage inflammatory protein 
ml   milliliter 
mm   millimeter 
mM   millimolar 
MMC   mucosal mast cell 
MMP   matrix metalloproteinase 
mRNA   messenger RNA 
MTS                               3-(4,5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)- 
2-(4-sulfophenyl)-2H-tetrazolium 
MZL   primary cutaneous marginal zone B-cell lymphoma 
n   number 
ND   not degranulated 
NEA   non-essential amino acid solution 
NGF   nerve growth factor 
NHL   non-Hodgkin lymphoma 
nm   nanometer 
nM   nanomolar 
NO   nitric oxide 
ns   not significant 
PAF   platelet-activating factor 
PCL   primary cutaneous lymphoma 
PCR   polymerase chain reaction 
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PDGF   platelet-derived growth factor 
pg   picogram 
PG   prostaglandin 
pH   negative logarithm of the hydrogen ion concentration 
PLEO                             primary cutaneous small/medium-sized pleomorphic  
T-cell lymphoma 
Pseudolym  pseudolymphoma 
Rev   reverse 
RNA   ribonucleic acid 
rpm   rounds per minute 
RPMI   roswell park memorial institute medium 
s.c.   subcutaneous 
SCF   stem cell factor 
SD   standard deviation 
SDS   sodium dodecyl sulfate 
sec   seconds 
SEM   standard error of the mean 
SS   Sézary syndrome 
TGF   transforming growth factor 
TNF   tumor necrosis factor 
TPA   12-O-tetradecanoylphorbol 13-acetate 
U   unit 
UV   ultraviolet 
V   volt 
VEGF   vascular endothelial growth factor 
Vol   tumor volume 
w/v   weight per volume 
WHO   World Health Organization 
WT   wildtype 
x   fold
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1. Introduction 
 
1.1. Mast cells 
In 1878, Paul Ehrlich discovered cells with large cytoplasmic granules that he 
named "mast cells".1 First, mast cells were believed to be a component of the 
connective tissue, derived from undifferentiated mesenchymal cells.2,3 Today, 
we know that mast cells are bone marrow-derived hematopoietic cells. 
Hematopoietic stem cells give rise to mast cell progenitors, which circulate in 
the blood and enter the tissues, where differentiation and maturation into 
mature mast cells takes place (Figure 1).4 However, it is still controversially 
discussed whether the mast cell progenitor is derived directly from a pluripotent 
precursor or from the myeloid lineage.  
 
 
 
Figure 1. Mast cell development. Mast cells originate from hematopoietic stem cells (HSC) in 
the bone marrow that give rise to mast cell progenitors (MCP). These mast cell progenitors are 
released into the blood and circulate until they migrate into the tissues, where they finally 
differentiate into mature mast cells. MMC, mucosal mast cells; CTMC, connective tissue mast 
cells. 
 
The phenotype of mature mast cells varies depending on the tissue 
microenvironment. Human mast cell subpopulations are divided into MCTC cells, 
designated to their tryptase and chymase content, and MCT cells that only 
contain tryptase. In analogy to human mast cells, also different types of murine 
mast cells exist. In mice, one can distinguish between mucosal mast cells 
(MMC), located within mucosal epithelia and connective tissue mast cells 
(CTMC), located in skin, peritoneal cavity and submucosa.5 Because human 
MCT cells predominantly appear in the alveolar septa of the lung and in the 
small intestinal mucosa, they most closely correspond to mouse MMC, whereas 
human MCTC cells resemble mouse CTMC.
6  
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Due to the preferred location of mast cells in tissues exposed to the 
environment such as skin, airways and gastrointestinal tract7-9, they are one of 
the first immune cells to interact with invading pathogens10,11 or antigens.12,13 
Thus, mast cells are predestined for performing important functions in 
innate10,14,15 and adaptive14,16-18 immunity. Furthermore, several studies 
reported on a possible role of mast cells in wound healing, tissue remodeling 
and transplant tolerance.19-21 Additionally, mast cells seem to contribute to diet-
induced obesity and diabetes.22 Moreover, a pathogenic role of mast cells was 
described for rheumatoid arthritis, multiple sclerosis and atherosclerosis23-26 as 
well as for different human malignancies, as described in detail in section 1.5.  
Mast cells are long-lived cells that can re-enter the cell cycle and proliferate 
after appropriate stimulation.27 Furthermore, the increased recruitment and/or 
retention, and local maturation of mast cell progenitors can contribute to the 
expansion of mast cell populations.6,28 The best-characterized activation 
pathway in mast cells is their activation through immunoglobulin E (IgE), which 
binds to the high affinity IgE receptor Fcε-receptor I (FcεRI).29 In mice, activation 
through IgG1 and FcγRIII is also possible. Besides, a large variety of other 
immunological and non-immunological signals can induce mast cell activation.27 
Depending on the type and concentration of the activation signal, mast cells can 
release either all classes of mediators at high levels via degranulation or may 
release certain mediators more selectively by secretion.14 This offers the 
possibility to respond to the requirements of the specific biological process with 
large variation. In addition, being rechargeable, mast cells can also participate 
in multiple cycles of mediator release. Furthermore, mast cells can functionally 
interact with other cell types, including T-cells, B-cells, dendritic cells (DC) and 
eosinophils, both by releasing mediators and by cell-cell interactions.  
 
1.2. Models for investigating mast cell functions in vivo 
Over the past 30 years, Kit-mutant mice like WBBF1-KitW/W-v and C57BL/6 KitW-
sh/W-sh have usually been used for the investigation of mast cell biology in 
vivo.4,30 KitW contains a point mutation that encodes for a truncated Kit protein, 
which lacks the transmembrane domain and is therefore not expressed on the 
cell surface, KitW-v shows a mutation in the Kit tyrosine kinase domain that 
decreases the kinase activity of the receptor and KitW-sh contains an inversion 
Introduction 
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mutation of the transcriptional regulatory elements upstream of the Kit 
transcription start site on mouse chromosome 5.14,17,27 Adult WBBF1-KitW/W-v 
and C57BL/6 KitW-sh/W-sh mice are deficient in mast cells and melanocytes.4 In 
the WBBF1-KitW/W-v strain, the number of mast cells in the skin, stomach, cecum 
and mesentery is reduced to less than 1% compared to congeneic controls. 
Additionally, WBBF1-KitW/W-v mice have several other abnormalities, such as 
macrocytic anemia, a decrease in the number of bone marrow and blood 
neutrophils, sterility and a decreased number of intestinal cells of Cajal.4,28,30  
The mast cell-deficient strain C57BL/6 KitW-sh/W-sh is fertile and not anemic.30,31 
C57BL/6 KitW-sh/W-sh animals are largely devoid of mast cells in the tongue, 
trachea, lung, stomach, spleen, small intestine, mesentery, peritoneum and 
inguinal lymph nodes. In the skin, 1.2% of the normal number of mast cells are 
still present.30 However, C57BL/6 KitW-sh/W-sh mice also show abnormalities like 
splenomegaly, thrombocytosis, neutrophilia, and decreased numbers of F4/80-
positive cells in the bone marrow.32 
In contrast to the Kit-mutant lines used up to now, recently developed mouse 
models of inducible (Mcpt5-Cre/iDTR) and constitutive (Mcpt5-Cre/R-DTA) mast 
cell deficiency33,34 show an otherwise normal immune system. For creating 
these new mouse models, bacterial artificial chromosome (BAC) transgene 
technology was employed to express Cre recombinase under the control of the 
mast cell-specific promoter mast cell protease-5 (Mcpt5).33 The constructs were 
injected into C57BL/6 oocytes for random integration into the mouse genome. 
To develop a mouse model of inducible mast cell deficiency, Mcpt5-
Cre/iDTR33,34 mice were generated by breeding the mast cell-specific transgenic 
line Mcpt5-Cre to the iDTR line, which is characterized by expression of a 
simian diphtheria toxin receptor (DTR) in cells that have deleted a loxP-flanked 
stop cassette by Cre-mediated recombination (Figure 2).35 Mcpt5-Cre+/iDTR+ 
mice show efficient and specific depletion of connective tissue mast cells upon 
intraperitoneal injections with diphtheria toxin (DT). A mouse model of 
constitutive mast cell deficiency, was obtained by crossing the mast cell-specific 
transgenic line Mcpt5-Cre to the R-DTA line36 (Figure 3). These mice express 
diphtheria toxin (DT) under the control of a loxP-flanked stop cassette. The 
loxP-flanked cassette prevents DT expression in the absence of Cre activity. 
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Figure 2. Mcpt5-Cre/iDTR – A mouse model of inducible mast cell deficiency. 
Intraperitoneally injected diphtheria toxin (DT) binds to the receptors on the surface of 
connective tissue mast cells, which leads to apoptosis of these cells. DTR, diphtheria toxin 
receptor; DT, diphtheria toxin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Mcpt5-Cre/R-DTA – A mouse model of constitutive mast cell deficiency. Upon 
Cre activity connective tissue mast cells express diphtheria toxin (DT), which leads to apoptosis 
of these cells. DT, diphtheria toxin 
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1.3. Hallmarks of cancer 
The hallmarks of cancer (Figure 4) include, according to Hanahan and 
Weinberg37, ten different mechanisms as shown below: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Hallmarks of cancer. Adapted from Hanahan and Weinberg, 2011
37 
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1.3.1. Sustaining proliferative signaling 
Whereas normal tissue controls the production and release of growth-promoting 
signals to ensure constant cell numbers and intact tissue architecture, tumor 
cells deregulate these signals. The enabling signals are conveyed by growth 
factors that bind cell surface receptors. Sources of these proliferative signals 
are still largely unknown. 
 
1.3.2. Evading growth suppressors 
Besides limitless growing, tumor cells are able to circumvent programs that 
negatively regulate cell proliferation, which are mostly dependent on tumor 
suppressors. Additionally, contact inhibition which, in dense cell populations, 
also yields to a suppressed cell proliferation is abolished in many cancers. 
Furthermore, deactivating the TGF-β pathway, known for its antiproliferative 
effects, promotes malignancy. 
 
1.3.3. Avoiding immune destruction 
Immune surveillance is usually responsible for recognizing and eliminating the 
majority of abnormal cells. Tumor cells are often able to avoid detection by the 
immune system or can limit the extent of being killed. For example, tumor cells 
can "paralyze" infiltrating cells of the immune system by secreting TGF-β or 
other immunosuppressive factors. Moreover, they can also actively recruit 
immunosuppressive cells, such as regulatory T-cells and myeloid-derived 
suppressor cells. 
 
1.3.4. Enabling replicative immortality 
In order to generate tumors, tumor cells aquire unlimited replicative potential. In 
contrast, normal cells can only pass through a limited number of successive cell 
growth and cell divison cycles. In the end, normal cells become senescent, 
meaning they enter a nonproliferative, but viable state. It may occur that some 
of these cells escape from this state and acquire unlimited replicative potential. 
Cells that undergo this transition are then called "immortalized". They may 
proceed to form tumors due to their ability to maintain telomeric DNA at lengths 
sufficient to avoid undergoing senescence or apoptosis, achieved by 
upregulating the expression of telomerase. 
Introduction 
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1.3.5. Tumor-promoting inflammation 
Tumors are infiltrated by cells of the innate and adaptive immune system and 
mirror inflammatory conditions. Historically, such immune responses were 
thought to reflect an attempt of the immune system to eradicate tumors. Today, 
it is well recognized that the tumor-associated inflammatory response can also 
have the opposite effect of enhancing tumorigenesis and progression. 
Inflammation can contribute to different hallmarks of cancer by supplying a large 
variety of molecules to the tumor microenvironment that promote tumors, for 
example growth factors to sustain proliferative signaling, survival factors that 
limit cell death, proangiogenic factors and extracellular matrix-modifying 
enzymes that facilitate angiogenesis, invasion and metastasis. 
 
1.3.6. Activating invasion and metastasis 
Invasion and metastasis is a multistep process, starting with local invasion, 
followed by intravasation of tumor cells into nearby blood and lymphatic 
vessels, transition of tumor cells through the lymphatic and hematogenous 
systems, extravasation of tumor cells from the lumina of these vessels into the 
parenchyma of distant tissues, formation of micrometastasis and finally by 
growth of micrometastatic lesions into macroscopic tumors. 
 
1.3.7. Inducing angiogenesis 
Tumors need nutrients and oxygen and can eliminate metabolic waste and 
carbon dioxide. Therefore, angiogenesis, which means sprouting of new 
vessels from existing ones, is necessary to generate a tumor-associated 
vasculature. During tumor progression, an "angiogenic switch" causes 
continuous sprouting of normal vasculature. Tumor vasculature is marked by 
early capillary sprouting, convoluted and excessive vessel branching, distorted 
and enlarged vessels, erratic blood flow, leakiness and abnormal levels of 
endothelial cell proliferation and apoptosis.38 The best-studied inducer of 
angiogenesis is vascular endothelial growth factor (VEGF). VEGF gene 
expression is upregulated by hypoxia as well as by oncogene signaling. 
Furthermore, VEGF ligands are sequestered in the extracellular matrix in latent 
forms that are subject to release and activation by extracellular matrix-
degrading proteases, like for example matrix metalloproteinase-9 (MMP-9).  
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In addition, other proangiogenic signals, like fibroblast growth factor (FGF), 
have been implicated in sustaining tumor angiogenesis. 
 
1.3.8. Genome instability and mutation 
As tumor progression is a multistep process, every step offers the opportunity 
for mutations and deregulating gene expression. Due to the inherent ability to 
detect and resolve DNA defects, the rate of spontaneous mutations is usually 
very low. Tumor cells often show increased rates of mutations. This mutability is 
also achieved through increased sensitivity to mutagenic agents, through a 
breakdown in one or several components of the genomic maintenance 
machinery, or through both mechanisms. Additionally, the accumulation of 
mutations is accelerated by comprising the surveillance systems that normally 
monitors genomic integrity and transfers genetically damaged cells into 
senescence or apoptosis. 
 
1.3.9. Resisting cell death 
Programmed cell death by apoptosis is a natural barrier to cancer development. 
Tumor cells have developed many different strategies to limit or circumvent 
apoptosis, for example loss of tumor suppressor functions, increased 
expression of antiapoptotic regulators (Bcl-2, Bcl-xL) or survival signals (Igf1/2) 
and downregulation of proapoptotic factors (Bax, Bim, Puma). 
 
1.3.10. Deregulating cellular energetics by reprogramming  
the energy metabolism 
Under aerobic conditions, normal cells process glucose via glycolysis into 
pyruvate and thereafter into carbon dioxide through mitochondrial oxidative 
phosphorylation. Tumor cells can reprogram their glucose metabolism by 
shifting their energy production largely to glycolysis. Besides, reliance on 
glycolysis is of particular importance under hypoxic conditions within many 
tumors. Furthermore, increased glycolysis allows the distribution of glycolytic 
intermediates into various biosynthetic pathways, which facilitate the 
biosynthesis of macromolecules required for assembling new cells. 
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1.4. Mast cell mediators and their potential role in tumorigenesis 
Upon activation, mast cells exert their biological functions by releasing 
preformed as well as de novo synthesized mediators. Mast cells produce a 
broad array of such mediators and cell-cell signaling molecules. About thirty 
different cytokines, chemokines as well as other metabolites have been shown 
to be produced by mast cells.39 They can be grouped into three major classes.12 
First, preformed and granule-associated mediators are produced like histamine, 
serotonin, proteases like tryptase and chymase as well as TNF, VEGF and 
FGF. Second, newly synthesized lipid mediators are released, namely the 
leukotrienes LTC4 and LTB4 and the prostaglandins PGD2 and PGE2. Third, de 
novo synthesized cytokines and chemokines are produced. In tumor biology, 
these mediators can either have "beneficial" effects on tumor growth, causing 
progression and spread of the tumor, or "detrimental" effects, limiting the growth 
of the tumor. To mention just some of these mediators, histamine and growth 
factors like NGF, SCF, PDGF and TGF-β promote tumor development, whereas 
heparin, VEGF, FGF and CXCL8 (IL-8) are known to induce angiogenesis, 
which is an essential feature for tumorigenesis. Some of these growth factors 
can also serve as mast cell chemoattractants in a feedback loop. On the other 
hand, mast cell-produced cytokines may also participate in anti-tumor 
responses and tumor rejection by promoting inflammation (IL-1, IL-2, IL-6, IL-
10, TNF-α, IFN-γ) or by inducing tumor cell apoptosis (IL-4, IL-13). Table 1 and 
2 summarize mast cell mediators and their functions concerning tumor growth. 
However, investigations on the role of specific mast cell products in tumor 
development, especially concerning the balance between pro- and anti-
inflammatory mechanisms, are still at the very beginning. 
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Table 1. Mediators produced by mast cells exerting beneficial effects on tumor growth. 
 
 
 
 
 
Table 2. Mediators produced by mast cells exerting detrimental effects on tumor growth. 
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1.5. Mast cells in tumors 
In a large variety of cancers, immune cells of the tumor microenvironment have 
been demonstrated to play crucial roles in tumor biology.37,40 In particular, 
tumor-associated macrophages, myeloid-derived suppressor cells (MDSC) and 
T regulatory cells (Tregs) participate in the development of tumors by regulating 
various hallmarks of cancer, like proliferation, angiogenesis, immunomodulation 
and tissue remodeling.  
The accumulation of mast cells especially in the periphery of tumors was first 
reported by Westphal in 1891.41 But also recent studies demonstrated 
impressively that mast cells serve as critical regulators of the tumor 
microenvironment.41-43 Many types of solid cancers and hematologic 
malignancies show an increased number of mast cells.44-55 Mast cell counts 
often also correlate with tumor stage, prognosis and invasiveness, suggesting a 
protumorigenic role of mast cells in these malignancies.44-51 More precisely, 
increased numbers of mast cells have been reported to correlate with poor 
prognosis in lymphoid neoplasms such as Hodgkin´s lymphoma47, B-cell non-
Hodgkin’s lymphoma50 and multiple myeloma56. Similar data have been 
obtained in solid cancers, such as pancreatic cancer57, hepatocarcinoma and 
cholangiocarcinoma49, prostate cancer44, neurofibroma48 and melanoma46,58.  
In summary, the previous studies demonstrated that: (1) Mast cells participate 
in creating a microenvironment that promotes tumor growth. (2) Mast cell-
deficient mice show an impaired carcinogenesis and reduced tumor neo-
angiogenesis.59,60 (3) Pharmacological inhibition of mast cell degranulation can 
inhibit tumor growth.60  
In contrast to the protumorigenic role of mast cells described for a large number 
of tumors, mast cells were also reported to exert antitumorigenic effects in 
certain malignancies, for example by supporting cancer rejection.
52-54
 In 
colorectal cancer, infiltrates of mast cells have been associated with lower rates 
of lymph node metastasis and distant metastasis.52 Also, in breast cancer, 
stromal mast cells were found to correlate with a favorable prognosis.53,54 
Additionally, mast cells even showed plasticity by exerting both detrimental and 
beneficial effects in the same cancer entity depending on the tumor stage, as 
for example elegantly demonstrated for prostate adenocarcinoma.44  
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It has been speculated that mast cells remodel the tumor microenvironment 
through release of cytokines and chemokines upon degranulation as well as 
through interactions with other cell types.61 Aggregation of eosinophils together 
with mast cells has also been described to correlate with poor prognosis, for 
example in Hodgkin´s lymphoma.62 Apart from the interaction of mast cells with 
other immune cells of the tumor microenvironment, it is also conceivable that 
mast cells modulate other stromal structures such as blood vessels or 
extracellular matrix. As an example, mast cells may indirectly participate in 
tumor development by producing VEGF that in turn stimulates tumor growth 
through enhanced tumor neo-angiogenesis. Supporting this hypothesis, in lung 
cancer63 and squamous cell carcinomas of the esophagus64 and cervix65, mast 
cell infiltrates correlated with both microvessel density and tumor progression. 
The complex functions of mast cells in tumor biology may in part be related to 
the differential release of mediators, but specific effects on tumor growth are still 
poorly understood.  
 
1.6. Primary cutaneous lymphoma 
Cutaneous lymphomas are clonal lymphoid neoplasms, which belong to the 
group of extranodal non-Hodgkin´s lymphomas (NHL).66-69 They usually reflect 
a clonal proliferation of lymphocytes in the skin. The annual incidence is 
estimated at 1/100.000.67 By definition one has to distinguish between 
secondary cutaneous lymphomas, as manifestations of nodal or other 
extranodal lymphomas also involving the skin, and primary cutaneous 
lymphomas (PCL).  
As an example for a skin tumor in which the role of mast cells had not been 
described yet, we investigated primary cutaneous lymphomas (PCL). In PCL, 
functional interactions between neoplastic cells and their microenvironment are 
largely unknown. PCL are a clinical and histological distinct group of T- or B-cell 
malignancies that originate in the skin and usually remain localized to the skin 
for a longer period of time. In Europe, cutaneous T-cell lymphomas (CTCL) 
constitute about 75-80% of all PCLs, cutaneous B-cell lymphomas (CBCL) 20-
25%, but different distributions have been observed in other parts of the world.66 
Diagnosis and classification of primary cutaneous lymphomas into CTCL and 
CBCL and their subtypes is based on a combination of clinical, histological and 
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immunophenotypical data. The most common subtypes of CTCL include 
mycosis fungoides (MF), Sézary syndrome (SS) and lymphomatoid papulosis 
(LP), whereas CBCL are subdivided into primary cutaneous marginal zone B-
cell lymphoma (MZL), primary cutaneous follicle center lymphoma (CFBCL) and 
primary cutaneous diffuse large B-cell lymphoma (BCL).  
Clinical manifestation and prognosis of PCL are highly variable and depend on 
the subtype and stage of the disease.70,71 For example, early stages of MF, 
characterized by eczematous skin lesions resulting from inflammation 
associated with proliferation of malignant cells in the epidermis, typically run an 
indolent course.70 More advanced stages of MF show intradermal tumors, which 
arise from poorly differentiated subclones of malignant cells that spread into 
deeper layers of the skin and later into peripheral blood, lymph nodes and 
internal organs. In these advanced stages, conventional therapies can achieve 
only short-term clinical responses and median survival is less than three years. 
The prognosis is even worse in patients with SS, the leukemic variant of CTCL. 
In contrast, most patients with CBCL show stable nodular lesions associated 
with an indolent course.72 
Involvement of immune cells is suggested by elevated levels of inflammatory 
cytokines in plasma and skin sections of CTCL patients, such as IL-1β, IL-7, IL-
15, IL-17, IL-18 and IL-23.73-75 Recent investigations reported on significant 
expression of IL-17 in cells and tissues from patients with MF and SS.73,74 IL-17 
is known to participate in proinflammatory responses by initiating the production 
of various cytokines (IL-6, G-CSF, GM-CSF, IL-1β, TGF-β1, TNF), chemokines 
(CXCL8 and CCL2), and prostaglandins (PGE2) from other cell types such as 
epithelial cells, keratinocytes, endothelial cells, fibroblasts, macrophages and 
potentially mast cells. In CTCL, it has been shown that IL-2 and IL-15 are able 
to up-regulate the expression of IL-17 in neoplastic T-cells.
74
 CTCL lesions are 
known to exhibit increased angiogenesis and several angiogenic and 
inflammatory proteins that are induced by IL-17 (for example TNF, CCL20, 
MMP-9, COX-2, VEGF and CXCL8) are also expressed in CTCL lesions.76-78 
Interestingly, a recent study using a mouse model of CTCL reported on 
increased numbers of macrophages and neutrophils and showed that tumor 
growth is reduced upon depletion of macrophages.79 
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2. Aims 
 
Mast cells infiltrate many types of cancers. Recent studies demonstrated that 
mast cells actively participate in modulating tumor growth, either by directly 
affecting growth and invasiveness of tumor cells or by indirectly regulating the 
tumor microenvironment, e.g. by interacting with other immune cells, inducing 
neo-angiogenesis or degrading extracellular matrix, which then promotes tumor 
growth. However, the precise role of mast cells in tumors remains largely 
unknown. Therefore, the present study aims to clarify specific functions of mast 
cells in tumor biology addressing the following four goals: 
 
 
1. To explore numbers of mast cells and their correlation with tumor growth, 
we decided to initially investigate mast cell counts in primary cutaneous 
lymphoma (PCL) as an example of a tumor entity, in which mast cells have 
not been addressed to date. More specifically, we will analyze the number 
and distribution of mast cells in different subtypes of PCL compared to 
normal skin and inflammatory cutaneous diseases, such as psoriasis and 
atopic dermatitis. In addition, hypothesizing that mast cells are activated in 
the tumor microenvironment of PCL, we will explore mast cell degranulation 
in PCL. Furthermore, we will correlate mast cell numbers and degranulation 
with the course and prognosis of different PCL subtypes. 
 
 
2. To further elucidate the contribution of mast cells to tumor growth, we will 
use new transgenic mouse models with inducible or constitutive selective 
deficiency of connective tissue mast cells and analyze tumorigenesis in 
these models compared to control mice. Here, we will investigate different 
subcutaneously injected tumors, namely the murine lymphoma cell line EL4, 
the pancreatic adenocarcinoma cell line Pan02 and the Lewis lung 
carcinoma cell line LLC, as well as chemically induced carcinogenesis. 
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3. To clarify the effect of specific mast cell products on tumor growth, we will 
first analyze whether supernatant of human or murine mast cells stimulates 
cytokine production and proliferation of primary PCL cells and human or 
murine lymphoma cell lines. Next, we will investigate levels of different 
cytokines in supernatants of human and murine mast cells using a 
cytometric bead array approach. 
 
 
4. To address the role of mast cells in tumor neo-angiogenesis, we will 
analyze vessel density in PCL and in the murine EL4 tumor model. We will 
also investigate growth of EL4 tumors in mast cell-specific VEGF knockout 
mice. 
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3. Material and Methods 
 
3.1. Material 
3.1.1. Chemicals and solutions 
Standard chemicals and solutions were purchased from: 
Biochrom AG, Berlin, Germany 
Brenntag, Mülheim, Germany 
Gibco/Invitrogen, Karlsruhe, Germany 
Merck, Darmstadt, Germany 
Roth, Karlsruhe, Germany 
Serva, Heidelberg, Germany 
Sigma-Aldrich, Taufkirchen, Germany 
StarLab, Hamburg, Germany 
 
Product Company 
Acetone Roth 
Agarose StarPure StarLab 
Calcium ionophore A23187 Sigma-Aldrich  
Cromolyn sodium salt Sigma-Aldrich 
Dimethyl sulphoxide (DMSO) Sigma-Aldrich 
Disodium hydrogen phosphate (Na2HPO4) Merck 
Dulbecco´s Modified Eagle Medium (DMEM, 1x) Gibco/Invitrogen 
EDTA (1% (w/v) in PBS, cell culture) Biochrom AG 
Ethanol (≥ 99.5%) Roth 
Ethylenediaminetetraacetic acid (EDTA) Roth 
Fetal bovine serum (FBS) Biochrom AG 
Hanks´ Balanced Salt Solution (HBSS) Sigma-Aldrich 
Hydrochloric acid (HCl) Roth 
Iscove´s Modified Dulbecco´s Medium (IMDM, 1x) Gibco/Invitrogen 
Isopropanol Brenntag 
L-glutamine (200 mM) Biochrom AG 
Non-essential amino acid solution (NEA, 100x) Sigma-Aldrich 
Penicillin/Streptomycin (10.000 U/ml / 10.000 µg/ml) Biochrom AG 
Potassium chloride (KCl) Roth 
Potassium dihydrogen phosphate (KH2PO4) Roth 
Roswell Park Memorial Institute (RPMI) medium 1640 (1x) Gibco/Invitrogen 
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Roti®-Histofix (4%) Roth 
Sodium acetate (C2H3NaO2) Merck 
Sodium chloride (NaCl) Roth  
Sodium dodecyl sulfate (SDS) Serva 
Sodium pyruvate (100 mM) Gibco/Invitrogen 
Tris (HOCH2)3CNH2) Roth 
Trypsin (2.5%, 10x) Gibco/Invitrogen 
β-Mercaptoethanol (50 mM) Gibco/Invitrogen 
 
Table 3. Frequently used chemicals and solutions. 
 
3.1.2. Buffers 
Used buffers were prepared with deionized water at room temperature. 
Buffer components Concentration 
PBS 
NaCl 
KCl 
KH2PO4 
Na2HPO4 
 
 
136 mM 
 2.6 mM 
 1.5 mM 
010 mM 
TE  
Tris-HCl (pH 8.0) 
EDTA 
 
 
010 mM 
001 mM 
TAE 
Tris-HCl (pH 8.0) 
C2H3NaO2  
EDTA 
 
 
040 mM 
020 mM 
001 mM 
Tail lysis 
Tris-HCl (pH 8.0) 
EDTA 
NaCl 
SDS 
 
 
200 mM 
050 mM 
100 mM 
1% (w/v) 
Table 4. Chemical composition of frequently used buffers. 
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3.1.3. Single-stranded oligonucleotides 
All single-stranded oligonucleotides were purchased lyophilized, in HPLC 
quality, from metabion international AG, Martinsried, Germany. 100 µM stock 
solutions were prepared according to the manufacturer´s instructions in ddH2O. 
For use in PCR, stocks were diluted 1:10. 
 
3.1.3.1. Genotyping 
Name Sequence Bands 
Mcpt5-Cre 
Mcpt5-CreUP  
CreSeq1b-DO 
Mcpt5-Ex1-DO3 
 
 
5’ACAGTGGTATTCCCGGGGAGTGT3’ 
5’GTCAGTGCGTTCAAAGGCCA3’ 
5’GCTTTGGTGCTGGAACCCAGGA3’ 
 
WT         224 bp 
Cre+       224 bp 
               554 bp 
iDTR 
Mutant  
Common 
WT Rev 
 
 
 
5’CATCAAGGAAACCCTGGACTACTG3’ 
5’AAAGTCGCTCTGAGTTGTTAT3’ 
5’GGAGCGGGAGAAATGGATATG3’ 
 
WT         603 bp 
Homo     242 bp 
Hetero    242 bp     
               603 bp  
R-DTA 
Fwd 
Rev 
 
 
5’AAAGTCGCTCTGAGTTGTTAT3’ 
5’AAGAACGGAGCCGGTTGGCG3’ 
 
WT         no 
R-DTA+ 592 bp 
VEGF 
VEGF Rev  
VEGF Fwd 
 
5’TCCGTACGACGCATTTCTAG3’ 
5’CCTGGCCCTCAAGTACACCTT3’ 
 
WT         100 bp 
Homo     150 bp 
Hetero    100 bp     
               150 bp  
Table 5. Primer used for animal genotyping. 
 
3.1.3.2. Real-time PCR 
Name Sequence Reference 
IL-6 
IL-6 Fwd 
IL-6 Rev 
 
 
5’GGTACATCCTCGACGGCATCTC3’ 
5’GTTGGGTCAGGGGTGGTTATTG3’ 
 
          
80
 
TGF-β1 
TGF b1 Fwd 
TGF b1 Rev 
 
 
5’CAGAAATACAGCAACAATTCCTGG3’ 
5’TTGCAGTGTGTTATCCGTGCTGTC3’ 
 
          81 
GAPDH 
GAPDH sense 
GAPDH antisense 
 
 
5’CGGAGTCAACGGATTTGGTCGTAT3’ 
5’AGCCTTCTCCATGGTGGTGAAGAC3’ 
 
          
82
 
Table 6. Primer used for quantitative real-time PCR. 
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3.1.4. Laboratory equipment 
Equipment Description Company 
Balance Explorer Ohaus Europe, Nänikon, Schweiz 
Heraeus Biofuge Fresco DJB Labcare Ltd, Buckinghamshire, UK 
BioPhotometer - Eppendorf, Hamburg, Germany 
CCTV Monitor RMB 92 Rainbow CCTV, Costa Mesa, CA, USA 
CO2 Incubator Heracell 150i Thermo Scientific, Waltham, MA, USA 
Electrophoresis 
Power supply 
EPS 200 Pharmacia Biotech, Amersham, UK 
FACS Calibur E1274 BD Biosciences, Heidelberg, Germany 
ELISA Reader NJ-2000 InterMed, Tokyo, Japan 
LaminAir Flow HB 2448 Thermo Scientific, Waltham, MA, USA 
Heraeus Megafuge 1.0 DJB Labcare Ltd, Buckinghamshire, UK 
Microscope DM 4000 B Leica Camera AG, Solms, Germany 
Microwave - Bosch, Gerlingen, Germany 
pH-Meter CG 710 Schott, Mainz, Germany 
Thermal cycler StepOne Plus Applied Biosystems, Carlsbad, CA, USA 
Thermocycler T 3000 Biometra, Göttingen, Germany 
Thermomixer Compact Eppendorf, Hamburg, Germany 
UV light ECX-26.M Peqlab, Erlangen, Germany 
Vortexer VF2 IKA Labortechnik, Staufen, Germany 
Mitutoyo Quick Mini caliper Mitutoyo Europe, Neuss, Germany 
 
Table 7. Frequently used laboratory equipment. 
 
3.1.5. Software 
Software Version Company 
Adobe Photoshop 7.0 Adobe Systems Inc., Dublin, Ireland 
CellQuest Pro 5.2.1 BD Biosciences, Heidelberg, Germany 
Diskus 4.50.1638 Diskus, Königswinter, Germany 
EndNote X4 Bld 4845 Thomson Reuters, New York, NY, USA  
FCAPTM Array 1.0 BD Biosciences, Heidelberg, Germany 
GraphPad Prism 5.01 GraphPad Inc., San Diego, CA, USA 
Microsoft Excel  2010 Microsoft, Redmond, WA, USA 
Pannoramic Viewer 1.15 3DHistech Kft., Budapest, Hungary  
StepOne Software  2.1 Applied Biosystems, Carlsbad, CA, USA 
 
Table 8. Software used for data collection and analysis. 
Material and Methods 
26 
 
3.2. Methods 
3.2.1. Collection of cutaneous biopsies from patients  
with primary cutaneous lymphoma 
Cutaneous biopsies were obtained from 43 patients with PCL for diagnostic 
purposes and kindly provided by Dr. Max Schlaak, PD Dr. Peter Kurschat and 
Prof. Dr. Dr. Cornelia Mauch within the framework of the Z2 project of the 
SFB829 at the University of Cologne. All patients had attended the 
Hauttumorzentrum of the Department of Dermatology, University Hospital of 
Cologne between 1995 and 2010 (heads of the Hauttumorzentrum: Prof. Dr. Dr. 
Cornelia Mauch, PD Dr. Peter Kurschat; physicians: Dr. Max Schlaak, Prof. Dr. 
Christine Neumann). The diagnosis of PCL and assignment to disease 
categories and subtypes according to the WHO-EORTC classification were 
performed by Dr. Max Schlaak and PD Dr. Peter Kurschat and were based on 
established criteria.66,68 In addition, assignment to subtypes of PCL was 
confirmed by a histopathological reference center for PCL (Kempf and Pfaltz, 
Laboratory for Histological Diagnostics, Zurich, Switzerland). Out of the 43 
patients, 35 patients (81.4%) were diagnosed with CTCL and 8 patients (18.6%) 
with CBCL. Detailed clinical characteristics of all patients are listed in Table 10 
in the results section. For control, 12 biopsies from subjects with normal skin 
were kindly provided by Dr. Lukas Heukamp and Prof. Dr. Reinhard Büttner 
(Institute of Pathology, University Hospital of Cologne) and 24 biopsies from 
patients with inflammatory cutaneous diseases, namely 8 patients with 
psoriasis, 8 patients with atopic dermatitis and 8 patients with 
pseudolymphoma, obtained for diagnostic purposes were used. All procedures 
were approved by the Institutional Ethics Committee of the University of 
Cologne, Cologne, Germany, under written, informed patient consent and 
adherence to the declaration of Helsinki (AZ 08-144). Patients with CTCL were 
grouped in cooperation with Dr. Max Schlaak according to the ISCL/EORTC 
classification.71,83 Additionally, to also reflect the clinical course of PCL, patients 
with CTCL were divided in cooperation with Dr. Max Schlaak into those with 
stable or progressive disease, defining stable disease as maximally two topical 
treatments (e.g., UV irradiation, topical corticosteroids) and progressive disease 
as three or more topical and systemic treatments (e.g,. UV irradiation, topical 
corticosteroids, surgery, systemic therapy such as bexarotene or interferon 
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alpha). Progression-free survival was defined in cooperation with Dr. Sebastian 
Theurich and PD Dr. Dr. Michael von Bergwelt-Baildon (Department I of Internal 
Medicine, University Hospital of Cologne) as time span from initial diagnosis 
until first change of systemic therapy due to disease progression and recorded 
over 30 years. For Kaplan-Meier curves, the event criterion was defined as 
>100 mast cells/mm2. 
 
3.2.2. Histology 
Staining procedures were performed in cooperation with Dr. Lukas Heukamp 
and Prof. Dr. Reinhard Büttner (Institute of Pathology, University Hospital of 
Cologne) within the framework of the Z1 project of the SFB832 at the University 
of Cologne. 
 
3.2.2.1. Human samples 
Histological analysis of mast cells in human PCL was initiated by Dr. Max 
Schlaak and PD Dr. Karin Hartmann. These initial studies suggested an 
increase of mast cells in PCL. Therefore, sections of paraffin-embedded 
cutaneous biopsies from 43 patients with PCL and control subjects with normal 
skin and inflammatory cutaneous diseases were systematically evaluated by 
immunohistochemistry with antibodies against mast cell tryptase (pretreatment 
with 0.1% protease, staining with 1:3.000 dilution of antibody Dako 7052, Dako, 
Hamburg, Germany) and CD117 (Kit; pretreatment with citrate buffer pH 6.0, 
staining with 1:100 dilution of antibody Dako A4502, Dako, Hamburg, 
Germany). Evaluation of skin sections was performed by counting the number 
of tryptase- and CD117-positive mast cells under a Leica microscope with 
Diskus software at 200x magnification in 5 high power fields. Counts were used 
to calculate the mean number of mast cells per mm
2
. A comparison between 
stainings with antibodies against tryptase and CD117 showed highly consistent 
results. Results were, therefore, only expressed as tryptase-positive mast cells. 
For control, sections were also counted by Silke Leja (MTA, Department of 
Dermatology), as a second independent reviewer. 
To grade degranulation of mast cells, skin sections were assessed at 200x 
magnification and mast cells were semiquantitatively classified into 3 groups of 
not degranulated, moderately degranulated or extensively degranulated mast 
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cells.34 Sections were also stained by hematoxylin/eosin (H&E) following 
standard protocols in a routine histology laboratory. 
For analysis of microvessel density, sections of paraffin-embedded cutaneous 
biopsies from patients with MF and control patients with inflammatory 
cutaneous diseases were evaluated by immunohistochemistry with antibodies 
against CD31 (pretreatment with citrate buffer pH 6.0, staining with 1:500 
dilution of antibody Dako M0823, Dako, Hamburg, Germany) and CD34 
(pretreatment with citrate buffer pH 6.0, staining with 1:2000 dilution of antibody 
Cell Marque 134M-1, Cell Marque, Sierra College Blvd., Rocklin, CA, USA). 
Evaluation of skin sections was performed by recording the distribution of 
CD31- and CD34-positive microvessels with a minimal lumen size of 50 µm2 
and by counting their number under a Leica microscope with Diskus software at 
100x magnification in 5 high power fields. Counts were used to calculate the 
mean number of microvessels per mm2. A comparison between stainings with 
antibodies against CD31 and CD34 showed highly consistent results. Results 
were, therefore, only expressed as CD31-positive microvessels. 
 
3.2.2.2. Murine samples 
In order to detect mast cells in the different mouse models (as described 
below), punch biopsies of back skin were fixed in 4% formalin (Roti®-Histofix) 
over night and embedded in paraffin. Sections were stained by Giemsa stain 
and toluidine blue following standard protocols in a routine histology laboratory.  
For evaluation of microvessel density in the different mouse models (as 
described below), punch biopsies of back skin were embedded in paraffin and 
CD31 staining (pretreatment with citrate buffer pH 6.0, staining with 1:50 dilution 
of antibody Histonova DIA-310, Dianova, Hamburg, Germany) was performed. 
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3.2.3. In vitro experiments 
3.2.3.1. Cell isolation 
To obtain primary Sézary cells, CD4+ T-cells from a patient with Sézary 
syndrome were isolated from freshly collected blood, kindly provided by Dr. Max 
Schlaak, using the Macs Whole Blood Column Kit for CD4+ T-cells (Miltenyi 
Biotech, Bergisch Gladbach, Germany) and generated by culturing as described 
in section 3.2.3.2. Additionally, CD4+ T-cells from the blood of healthy donors, 
kindly provided by PD Dr. Karin Hartmann, were isolated as controls. 
Primary murine bone marrow-derived mast cells (BMMC) were isolated under 
sterile conditions from the femoral lavage of WT C57BL/6 mice.30 
 
3.2.3.2. Cell culture 
All cell cultures were maintained at 37°C in 5% CO2 in a humidified atmosphere. 
The human CTCL cell line Mac2B, originally derived from a patient with 
CD30+ALCL84, was kindly provided by Dr. Marshall Kadin (Department of 
Dermatology and Skin Surgery, Boston University School of Medicine, Roger 
Williams Medical Center, Providence, USA) and maintained in RPMI 1640 
medium containing 20% FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 
μg/ml streptomycin.  
Human CTCL cell lines MyLa, derived from a patient with MF85, and SeAx, 
derived from a patient with SS86, as well as the human B-cell lymphoma cell line 
BJAB, derived from African Burkitt-like lymphoma87, were kindly provided by Dr. 
Maria Karpova (Department of Dermatology, University Hospital Zurich, Zurich, 
Switzerland). All three cell lines were cultured in RPMI 1640 medium containing 
10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin and 
100 μg/ml streptomycin.  
The cell line Jurkat (originally called JM), a pseudodiploid human cell line that 
originated from a patient with acute T-cell leukemia88, was cultured in RPMI 
1640 medium containing 10% FBS, 4 mM L-glutamine, 100 U/ml penicillin and 
100 μg/ml streptomycin.  
Primary Sézary cells were cultured as described89 and kept in RPMI 1640 
medium containing 20% FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 
μg/ml streptomycin. Isolated CD4+ T-cells were maintained in RPMI 1640 
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medium containing 10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 
U/ml penicillin and 100 μg/ml streptomycin. 
The human mast cell line HMC1, originally derived from a patient with mast cell 
leukemia, was kindly provided by Dr. Joseph H. Butterfield (Mayo Clinic, 
Rochester, USA) and cultured in IMDM medium containing 10% FBS, 2 mM L-
glutamine, 50 µM β-mercaptoethanol, 100 U/ml penicillin and 100 μg/ml 
streptomycin.90 For our experiments, we used the subclone HMC1.2, which 
carries 2 Kit mutations, V560G and D816V. 
For mouse xenograft experiments, we used the mouse T-cell lymphoma cell line 
EL4, which was kindly provided by A. Gisselsson (Genovis, Malmö, Sweden) 
maintained in DMEM medium containing 10% FBS, 2 mM L-glutamine, 1 mM 
sodium pyruvate, 50 μM β-mercaptoethanol, 100 U/ml penicillin and 100 μg/ml 
streptomycin. 
Primary murine bone marrow-derived mast cells (BMMC) were isolated from the 
femoral lavage of WT C57BL/6 mice30 and generated by culturing in IMDM 
medium supplemented with 10 ng/ml recombinant murine IL-3 (PeproTech, 
Hamburg, Germany), 10% FBS, 100 U/ml penicillin and 100 μg/ml 
streptomycin.90 
Primary cells and cell lines described above grew in suspension, whereas the 
mouse cell lines Pan02 and LLC, which were also used in mouse xenograft 
experiments, represented adherent cells and were, therefore, cultured on plates 
and detached by treatment with a PBS/Trypsin/EDTA mixture. 
The mouse pancreas adenocarcinoma cell line Pan02, also known as Panc0291, 
was a kind gift from Dr. David Linehan´s Lab (Washington University School of 
Medicine, Department of Surgery, St. Louis, MO, USA). Cells were cultured in 
RPMI 1640 medium containing 20% FBS, 2 mM L-glutamine, 100 U/ml penicillin 
and 100 μg/ml streptomycin. 
Lewis lung carcinoma (LLC) cells, kindly provided by Dr. Axel Roers (Institute 
for Immunology, Medical Faculty Carl Gustav Carus, Technische Universität 
Dresden, Dresden, Germany), derived from spontaneously developing 
carcinoma of the lung of a C57BL/6 mouse, were maintained in DMEM medium 
containing 10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, non-essential 
amino acid solution (NEA, 1x), 100 U/ml penicillin and 100 μg/ml streptomycin.  
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3.2.3.3. Inhibition and stimulation of mediator release from mast cells 
To either inhibit or stimulate release of mediators from mast cells, 1x106 HMC1 
cells/ml were incubated with 1 ml cromolyn sodium salt (0.025 M) dissolved in 
HBSS or with 1 ml calcium ionophore A23187 (250 nM) dissolved in DMSO, 
respectively, for 30 minutes at 37°C. As control, cells were incubated with 
standard medium. Then, cells were washed and kept in standard medium for 6 
hours. After centrifugation, cell culture supernatant was frozen at -20°C and 
stored for future use in proliferation experiments and cytometric bead array 
(CBA) measurements, as described below. 
 
3.2.3.4. Cytometric bead array in cell culture supernatants 
For measurement of cytokine and chemokine levels in HMC1 supernatant, cells 
were either blocked or stimulated as described above and secretion of IL-2, IL-
4, IL-6, IL-10, IL-17A, TNF and IFN-γ using Human Th1/Th2/Th17 Cytokine Kit 
(BD Biosciences, Heidelberg, Germany), CXCL8, CCL5, CXCL9, CCL2 and 
CXCL10 using Human Chemokine Kit (BD Biosciences, Heidelberg, Germany) 
VEGF and basic FGF using Human Flex Sets (BD Biosciences, Heidelberg, 
Germany) together with Human Soluble Protein Master Buffer Kit (BD 
Biosciences, Heidelberg, Germany) as well as TGF-β1 using Human TGF-β1 
Single Plex Flex Set (BD Biosciences, Heidelberg, Germany) was measured by 
cytometric bead array (CBA) according to the manufacturer’s guidelines. 
For measurement of baseline cytokine levels in mouse BMMCs and EL4 cells, 
human CTCL cells, cell lines and control cells, 2x106 cells/ml of 4 week-old cells 
were cultured for 1 week under standard conditions described above and 
secretion of IL-2, IL-4, IL-6, IL-10, IL-17A, TNF and IFN-γ was measured in 
supernatants by cytometric bead array (CBA) according to the manufacturer’s 
guidelines (Human/Mouse Th1/Th2/Th17 Cytokine Kit, BD Biosciences, 
Heidelberg, Germany). 
For measurements of changes in cytokine and chemokine production in mouse 
EL4 cells and human CTCL cell lines Mac2B and SeAx, 6x105 cells/ml freshly 
thawed cells were incubated with or without mast cell supernatant. Human cell 
lines were stimulated for 48 hours with HMC1 supernatant and the mouse cell 
line with supernatant of BMMCs. Thereafter, cells were washed, counted and 
5x105 cells/ml were cultured again for 48 hours in standard medium. Cell culture 
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supernatants were collected and frozen at -20°C for CBA measurements. In 4 
separate experiments, each sample was measured 6 times. 
After acquisition of sample data using FACS (FACS Calibur, BD Biosciences, 
Heidelberg, Germany), cytokine and chemokine concentrations were calculated 
using FCAP™ analysis software (BD Biosciences, Heidelberg, Germany).  
 
3.2.3.5. Quantitative real-time PCR  
3.2.3.5.1. RNA isolation and reverse transcription into cDNA 
Mac2B and SeAx cells (6x105 cells/ml) were incubated with or without HMC1 
supernatant for 24 hours. After washing, 6x105 cells/ml were cultured again for 
6 hours in standard medium.  
Total RNA was extracted from harvested cells with RNeasy Mini Kit (Qiagen, 
Hilden, Germany) completed with QIAshredder (Qiagen, Hilden, Germany) and 
on-column DNase digestion (RNase-Free DNase Set, Qiagen, Hilden, 
Germany), according to the manufacturer´s instructions. RNA was then 
reversely transcribed into cDNA using the QuantiTect Reverse Transcription Kit 
(Qiagen, Hilden, Germany), according to the manufacturer´s instructions. 
 
3.2.3.5.2. RNA and cDNA quantification 
RNA and cDNA concentrations were determined by measuring the absorption 
at 260 nm on the BioPhotometer. At this wavelength absorption of 1 
corresponds to 40 µg/ml RNA and 50 µg/ml cDNA, respectively. 
 
3.2.3.5.3. Real-time PCR 
To quantify the amounts of IL-6 and TGF-β1 mRNA expression, real-time PCR 
was performed using Power SYBR Green PCR Master Mix (Applied 
Biosystems, Carlsbad, CA, USA), according to the manufacturer´s instructions. 
The used primer sequences are listed in section 3.1.3.2. Real-time PCR was 
then performed on a StepOne Plus cycler (Applied Biosystems, Carlsbad, CA, 
USA) using the following cycling profile: 95°C for 10 min, 40 cycles of 95°C for 
15 sec and 60°C for 1 min, followed by a melting curve analysis to prove the 
specificity of the PCR product by 95°C for 15 sec, 60°C for 1 min and 95°C for 
15 sec. Relative quantification of gene expression was determined by 
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normalization against GAPDH expression using the 2-CT method.92 In 4 
separate experiments, each sample was measured 3 times. 
 
3.2.3.6. Cell proliferation measurement 
Primary T-cells, primary Sézary cells, the CTCL cell lines Mac2B, MyLa and 
SeAx, Jurkat cells, the BJAB cell line and EL4 cells were cultured with and 
without mast cell supernatant for 80 hours. Human cell lines were cultured with 
HMC1 supernatant and mouse EL4 cells with BMMC supernatant. As positive 
control, cells were also cultured with a cytokine cocktail containing IL-1α, IL-1β, 
IL-2, IL-4 and IL-7 (Peprotech, Hamburg, Germany), described to stimulate cell 
growth. Additionally, SeAx and Mac2B cell lines were cultured with mast cell 
supernatant derived from HMC1 cells blocked by cromolyn as described above. 
After 48 hours, fresh mast cell supernatant, media or cytokine cocktail was 
added. Cell proliferation was measured at 4 hour intervals using the Cell Titer 
96® AQueous One Solution Assay (Promega, Mannheim, Germany). Briefly, 100 
µl cells and 20 µl MTS (3-(4,5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) were added per well in a 96-well plate and 
incubated for 1 h at 37°C and 5% CO2. Absorbance of formazan, which is 
converted from living cells by MTS, was measured at 490 nm in an ELISA 
reader. 
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3.2.4. In vivo experiments 
Mice were kept and bred under standard conditions in a pathogen-free barrier 
facility. All procedures were performed in accordance with institutional 
guidelines on animal welfare and were approved by the "Landesamt fuer Natur, 
Umwelt und Verbraucherschutz" of North Rhine-Westphalia (AZ K23, 24/06). 
 
3.2.4.1. Mouse strains 
For investigating mast cell biology in vivo, different mouse models were used. 
We used Mcpt5-Cre/iDTR33,34, a mouse model of inducible mast cell deficiency, 
generated by breeding the mast cell-specific transgenic line Mcpt5-Cre to the 
iDTR line35. Mcpt5-Cre+/iDTR+ mice show efficient and specific depletion of 
cutaneous and peritoneal mast cells upon intraperitoneal injections with 
diphtheria toxin. Furthermore, we used a mouse model of constitutive mast cell 
deficiency, breeding the mast cell-specific transgenic line Mcpt5-Cre to the R-
DTA line36. To generate mice lacking mast cell-derived VEGF, a VEGF floxed 
mouse strain93, with loxP sites flanking the third exon of the VEGF gene (kindly 
provided by Napoleone Ferrara, Genentech Inc., South San Francisco, CA, 
USA) was also bred to Mcpt5-Cre. For comparison, we also used the mast cell-
deficient C57BL/6 KitW-sh/W-sh line30, which shows several other defects in 
addition, due to a genetic conversion in the Kit gene promotor, as well as WT 
C57BL/6 animals. Mouse models are also described in detail in the introduction. 
All mice were generated on the C57BL/6 background. 
 
3.2.4.2. Genotyping 
3.2.4.2.1. DNA isolation 
Tail biopsies (approx. 5 mm) obtained from 3 week-old mice were incubated in 
500 µl tail lysis buffer (see section 3.1.2.) and 5 µl proteinase K (Fermentas, St. 
Leon-Rot, Germany) in a thermomixer at 800 rpm and 55°C over night. After 
centrifuging, DNA was isolated from the supernatant by adding 700 µl ice-cold 
isopropanol. Precipitated DNA was pelleted by centrifuging and discarding the 
supernatant. DNA was washed with 500 µl 70% ethanol in an additional 
centrifugation step. Afterwards, the DNA pellet was dried at room temperature 
for 15 min and at 55°C in a thermomixer at 300 rpm for another 15 min.  
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Then DNA was dissolved in 50 μl TE buffer (see section 3.1.2.) at 800 rpm and 
55°C in a thermomixer over night. DNA was stored at 4°C.  
 
3.2.4.2.2. Polymerase chain reaction (PCR) 
For PCR, 3 µl of template DNA were added to 22 µl reaction master mix 
containing 1x Dream Taq buffer (10x, Fermentas, St. Leon-Rot, Germany), 200 
nM of each primer (10 µM), 200 µM dNTP mix (10 mM, Fermentas, St. Leon-
Rot, Germany) and 0.05 U/μl Dream Taq Polymerase (5 U/ μl, Fermentas, St. 
Leon-Rot, Germany). Primers used for genotyping are listed in section 3.1.3.1. 
and cycling profiles are summarized in Table 9. 
 
 
Step Temperature (°C) Time Cycle number 
1 2 3 4 1 2 3 4 1 2 3 4 
1 95 94 94 95 5 min 3 min 3 min 10 min  
2 95 94 94 95 45 sec 30 sec 30 sec 15 sec 
29 35 38 29 3 57 61 56 55 1 min 1 min 30 sec 1 min 
4 72 72 72 72 45 sec 1 min 1 min 2 min 
5 72 72 72 72 7 min 2 min 10 min 5 min  
6 10 10 4 10 - - - -  
 
Table 9. Summary of PCR cycling profiles for genotyping.1:Mcpt5-Cre; 2:iDTR; 3:R-DTA; 
4:VEGF 
 
Denaturation (step 1) was followed by the appropriate number of cyles of steps 
2-4. In step 3, up to 1 min at primer-suitable annealing temperature, and in step 
4, 1 min per kb DNA to be amplified at synthesis temperature (72°C), was used. 
Amplification was completed in a final step at 72°C (step 5). 
 
3.2.4.2.3. Gel electrophoresis 
PCR products were mixed with 5 µl loading dye (6x, Fermentas, St. Leon-Rot, 
Germany) and directly loaded onto a 2% (w/v) agarose gel (1x TAE, 8 µl SYBR 
Safe DNA gel stain, Molecular Probes/Invitrogen, Karlsruhe, Germany). Gel 
electrophoresis was performed at 100 V for 30 min and bands were visualized 
under UV light. 
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3.2.4.3. Administration of diphtheria toxin 
Lyophilized diphtheria toxin (DT) (Sigma-Aldrich, Taufkirchen, Germany) was 
reconstituted in ddH2O to a stock solution of 1 mg/ml and aliquots were stored 
at -20°C. For each DT injection, aliquots were thawed on ice and diluted to a 
working concentration of 5 ng/µl in sterile PBS. Starting at the age of 6 weeks, 
Mcpt5-Cre+/iDTR+ and Mcpt5-Cre-/iDTR+ controls received 4 injections of 25 
ng DT/g bodyweight intraperitoneally at weekly intervals to deplete mast cells. 
For the first injection, 5 µg/g bodyweight of pyrilamine maleate salt (Sigma-
Aldrich, Taufkirchen, Germany), a H1 histamine receptor antagonist 
(antihistamine), was added to prevent possible anaphylaxis reactions. 
 
3.2.4.4. Subcutaneous injection of tumor cell lines  
and measuring tumor growth 
For mouse xenograft experiments, 3 different cell lines, namely EL4, Pan02 and 
LLC were used. For subcutaneous injections, cells were harvested and washed 
in HBSS (Sigma-Aldrich, Taufkirchen, Germany). LLC cells were additionally 
treated with accutase solution (Sigma-Aldrich, Taufkirchen, Germany) to 
prevent cells from clustering and washed again in HBSS. 10 week-old Mcpt5-
Cre+/iDTR+, Mcpt5-Cre-/iDTR+ (both after DT treatment), Mcpt5-Cre+/R-DTA+, 
Mcpt5-Cre-/R-DTA+, Mcpt5-Cre/VEGFfl/fl, C57BL/6 KitW-sh/W-sh and WT C57BL/6 
animals received 100 µl of 1x107 of either EL4, Pan02 or LLC cells/ml HBSS 
(1x106 cells/mouse) subcutaneously into the shaved flanks. Subsequently, 
tumor size was assessed 5 times weekly by direct measurement of the tumor 
region in three perpendicular directions using a Mitutoyo Quick Mini caliper 
(Mitutoyo Europe GmbH, Neuss, Germany). Measurements were recorded as 
tumor area (mm2) and tumor volume (mm3) from groups of 2-3 mice each with 
two tumors per mouse. Tumor area (A) was calculated by the formula: [A= 
tumor height x tumor width], and tumor volume (Vol) by the formula: [Vol= tumor 
height x tumor width x tumor depth]. During tumor experiments, Mcpt5-
Cre+/iDTR+ mice and Mcpt5-Cre-/iDTR+ controls continuously received DT 
injections (80 μl) subcutaneously around the tumors once weekly to sufficiently 
deplete mast cells. Experiments were terminated after tumors started to burst 
and cutaneous punch biopsies were taken from tumor regions and processed 
as described in section 3.2.2.2. 
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3.2.4.5. Two-step model of chemically induced skin carcinogenesis 
Backs of 10 week-old Mcpt5-Cre+/iDTR+, Mcpt5-Cre-/iDTR+ (both after DT 
treatment), C57BL/6 KitW-sh/W-sh and WT C57BL/6 animals were shaved and 
treated 3 days later with a single application of the tumor initiator DMBA (7,12-
Dimethylbenz[a]anthracene, Sigma-Aldrich, Taufkirchen, Germany). DMBA 
represents a powerful carcinogen inducing multiple necessary mutations that 
promote tumor development. Animals were treated with 50 µg DMBA dissolved 
in 200 µl acetone. During the following weeks, the tumor-promoting reagent 
TPA (12-O-tetradecanoylphorbol 13-acetate, phorbol 12-myristate 13-acetate, 
PMA, Sigma-Aldrich, Taufkirchen, Germany) was applied twice weekly (6 µg 
dissolved in 200 µl acetone per mouse) for a period of up to 20 weeks. Figure 5 
and Figure 6 show the treatment regimens for C57BL/6 KitW-sh/W-sh and WT 
C57BL/6 animals and for Mcpt5-Cre+/iDTR+ and Mcpt5-Cre-/iDTR+ animals, 
respectively. As controls, backs of mice were shaved and received topical 
applications of acetone (200 µl/mouse) instead of DMBA or TPA. The number of 
papillomas was recorded once weekly. Back skin biopsies were taken from 1 
animal of each group every 3 weeks, processed as described in section 
3.2.2.2., mast cells were counted under the microscope at 200x magnification in 
5 high power fields and the mean value per mm2  was calculated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Treatment regimen for 
Mcpt5-Cre+/iDTR+ and Mcpt5-Cre-
/iDTR+ animals. For mast cell depletion 
animals received DT i.p. injections once 
a week for 4 weeks and were then 
treated with DMBA. After that, they 
received TPA or acetone applications 
twice weekly for a period of 15 weeks. In 
addition, animals received subcutaneous 
DT injections once a week. 
Figure 5. Treatment regimen for 
C57BL/6 Kit
W-sh/W-sh
 and WT C57BL/6 
animals. Animals were treated once 
with DMBA and received TPA or 
acetone applications twice weekly for a 
period of 20 weeks. 
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3.2.5. Statistical analysis 
Statistical analyses were performed with GraphPad Prism (Version 5.01) 
software (GraphPad Software Inc., San Diego, CA, USA) using two-tailed 
Student’s t test. Clinical data were analyzed as Kaplan-Meier curves employing 
Log-rank test. Correlation analyses were performed using Spearman 
correlation. A P value of less than 0.05 was considered statistically significant. 
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4. Results 
While working on this dissertation, parts of this research were originally 
published in Blood. Rabenhorst A, Schlaak M, Heukamp LC, Förster A, 
Theurich S, von Bergwelt-Baildon M, Büttner R, Kurschat P, Mauch C, Roers A, 
Hartmann K. Mast cells play a protumorigenic role in primary cutaneous 
lymphoma. Blood. 2012;120(10):2042-2054. © the American Society of 
Hematology. In particular, data reported below on PCL and EL4 (sections 
4.1.1.-4.1.6., partly 4.1.8., 4.1.9., 4.2.1., partly 4.2.3.) were published there.94 
 
4.1. Mast cells in the microenvironment of human PCL 
4.1.1. Clinical characteristics of PCL patients participating in the study 
In order to explore the role of mast cells in the tumor microenvironment of 
primary cutaneous lymphoma (PCL), we initially investigated the number and 
distribution of mast cells in different categories of human PCL.  
Skin sections from 43 PCL patients (Table 10) were used for counting mast 
cells microscopically. The group consisted of 29 male (67.4%) and 14 female 
(32.6%) patients. The age ranged from 23 to 81 years, with a mean age of 56.7 
years. As mentioned in the material and methods section, patients were 
grouped on the basis of the clinical course of the disease. 32 patients (74.4%) 
exhibited stable disease and 11 patients (25.6%) belonged to the progressive 
group. Furthermore, out of the 43 patients, 35 patients (81.4%) were diagnosed 
with CTCL and 8 patients (18.6%) with CBCL. Within the CTCL group, 23 
patients had mycosis fungoides (MF), 3 patients folliculotropic mycosis 
fungoides (FMF), 4 patients CD30-positive primary cutaneous anaplastic large 
cell lymphoma (CD30+ALCL), 1 patient lymphomatoid papulosis (LP), 1 patient 
primary cutaneous small/medium-sized pleomorphic T-cell lymphoma (PLEO) 
and 3 patients Sézary syndrome (SS). Within the CBCL group, 3 patients were 
diagnosed with primary cutaneous marginal zone B-cell lymphoma (MZL), 3 
patients with primary cutaneous follicle center lymphoma (CFBCL) and 2 
patients with primary cutaneous diffuse large B-cell lymphoma (BCL).  
In addition, CTCL patients suffering from MF, FMF and SS were clustered 
according to ISCL/EORTC classification71,83 into 13 patients with stage IA 
(44.8%), 8 patients with stage IB (27.6%), 1 patient with stage IIA (3.4%), 4 
patients with stage IIB (13.8%), 2 patients with stage IIIB (6.9%) and 1 patient 
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with stage IVA (3.4%). Moreover, patients with MF, FMF and SS were also 
assigned to clinical stages, namely eczema (13 patients, 44.8%), plaque (10 
patients, 34.5%), tumor (3 patients, 10.3%) and SS (3 patients, 10.3%). 
For control, 12 subjects with normal skin and 24 patients with inflammatory 
cutaneous diseases such as psoriasis (n=8), atopic dermatitis (n=8) and 
pseudolymphoma (n=8) were used. 
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Parameters Number of patients 
All 
 
43 (100%) 
Gender 
Male 
Female 
 
 
29 (67.4%) 
14 (32.6%) 
Age at time of skin biopsy 
Mean 
Range 
 50 years 
 50 years 
 
 
56.7 years 
23 – 81 years 
12 (27.9%) 
31 (72.1%) 
Clinical course 
Stable 
Progressive 
 
 
32 (74.4%) 
11 (25.6%) 
Category 
CTCL 
CBCL 
 
 
35 (81.4%) 
08 (18.6%) 
CTCL subtypes 
MF 
FMF 
CD30+ALCL 
LP 
PLEO 
SS 
 
 
23 (53.5%) 
03 (07.0%) 
04 (09.3%) 
01 (02.3%) 
01 (02.3%) 
03 (07.0%) 
ISCL/EORTC stages of MF, FMF, SS 
IA (T1) 
IB (T2) 
IIA (T1,2) 
IIB (T3) 
IIIB (T4) 
IVA (T1-4) 
 
 
13 (44.8%) 
08 (27.6%) 
01 (03.4%) 
04 (13.8%) 
02 (06.9%) 
01 (03.4%) 
Clinical stages of MF, FMF, SS 
Eczema 
Plaque 
Tumor 
SS 
 
 
13 (44.8%) 
10 (34.5%) 
03 (10.3%) 
03 (10.3%) 
CBCL subtypes 
MZL 
CFBCL 
BCL 
 
03 (07.0%) 
03 (07.0%) 
02 (04.7%) 
 
Table 10. Clinical characteristics of PCL patients participating in the study. 
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4.1.2. Mast cell numbers are increased in primary cutaneous lymphoma 
Cutaneous biopsies of patients with PCL and controls were stained with 
antibodies against mast cell tryptase and CD117 (Kit). Evaluation of skin 
sections was performed by counting the number of tryptase- and CD117-
positive mast cells under a Leica microscope with Discus software at 200x 
magnification in 5 high power fields. Counts were used to calculate the mean 
number of mast cells per mm2. A comparison between the two different 
antibodies against mast cell tryptase and CD117 showed highly consistent 
results. Therefore, results were only expressed as tryptase-positive mast cells 
per mm2. As shown in Figure 7A and Figure 8, mast cells were significantly 
increased in patients with PCL compared to normal skin and inflammatory 
cutaneous diseases, with a similar increase in CTCL and CBCL. The mean 
number of mast cells in PCL mounted to an increase of more than 3-fold 
compared to normal skin and about 2-fold compared to inflammatory cutaneous 
diseases (144.4 ± 11.5 mast cells/mm2 in PCL (All), 38.8 ± 3.5 mast cells/mm2 
in normal skin (Ctrl), 78.0 ± 3.6 mast cells/mm2 in inflammatory cutaneous 
diseases (All), mean ± SEM). Interestingly, in nearly all CTCL and CBCL 
sections, infiltration of mast cells was particularly prominent at the periphery of 
the infiltrate (Figure 7B). Often, mast cells were found to even align along the 
rim of the infiltrate (Figure 8C). In contrast, the number of mast cells in the 
center of CTCL and CBCL was comparable with normal skin (Figure 7B). When 
we compared different subtypes of CTCL and CBCL, even though for some rare 
subtypes only few samples were available, the CTCL subtypes folliculotropic 
MF (FMF) and Sézary syndrome (SS) appeared to exhibit the most pronounced 
mast cell infiltration (Figure 7C). Clinically, both of these subtypes are 
characterized by a highly progressive course. 
 
 
 
 
 
 
 
 
Results 
43 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B                                                C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Mast cell numbers are increased in PCL. (A) Skin biopsies from patients with PCL 
(All; n=43) subdivided into patients with CTCL (n=35) and CBCL (n=8), from subjects with 
normal skin (Ctrl; n=12) and from patients with inflammatory cutaneous diseases (All; n=24) 
such as psoriasis (n=8), atopic dermatitis (AD; n=8) and pseudolymphoma (Pseudolym; n=8) 
were stained by immunohistochemistry with anti-tryptase antibody. The number of tryptase-
positive mast cells was analyzed by microscopic counting of 5 high power fields at 200x 
magnification and calculating the mean number of mast cells per mm
2
. Data represent the mean 
± SEM. Statistical significance was assessed by two-tailed Student´s t-test. (B) The number of 
tryptase-positive mast cells was counted separately in the center (filled columns) and in the 
periphery (striped columns) of PCLs. Data represent the mean ± SEM. Statistical significance 
was assessed by two-tailed Student´s t-test. (C) The number of tryptase-positive mast cells was 
analyzed in different PCL subtypes subdivided into CTCL patients with MF (n=23), FMF (n=3), 
CD30+ALCL (n=4), LP (n=1), PLEO (n=1), SS (n=3) and CBCL patients with MZL (n=3), 
CFBCL (n=3) and BCL (n=2) and from subjects with normal skin (Ctrl; n=12). Data represent the 
mean ± SEM. 
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Figure 8. Histological analyses showed that mast cell numbers are increased in PCL. (A) 
Normal skin, magnification 200x. (B) CTCL, plaque stage, magnification 200x. (C) CTCL, tumor 
stage, magnification 50x. (D) Psoriasis, magnification 150x. (E) Atopic dermatitis, magnification 
150x. (F) Pseudolymphoma, magnification 150x, staining of mast cells with anti-tryptase 
antibody (brown).  
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4.1.3. Mast cell numbers correlate with progression of 
primary cutaneous lymphoma 
To investigate whether progression of CTCL correlates with the number of mast 
cells, patients with MF, FMF and SS were grouped according to the 
ISCL/EORTC classification and, additionally, by means of the clinical course 
into patients with stable or progressive disease (Figure 9A, Table 10). Patients 
exhibiting more advanced stages of the disease (IIB-IVA; 278.5 ± 21.7 mast 
cells/mm2 in stage IIB; 254.8 ± 4.7 mast cells/mm2 in stage IIIB; 227.8 mast 
cells/mm2 in stage IVA; mean ± SEM) showed significantly increased numbers 
of mast cells compared to patients with stages IA (100.9 ± 7.7 mast cells/mm2; 
mean ± SEM) to IB (100.2 ± 13.6 mast cells/mm2; mean ± SEM). Similarly, 
patients with progressive disease showed increased mast cell numbers 
compared to stable patients (271.2 ± 13.7 mast cells/mm2 in progressive, 100.7 
± 6.8 mast cells/mm2 in stable patients, mean ± SEM). We also determined 
progression-free survival and found, as anticipated, that patients with advanced 
disease stages as well as progressive disease showed a significantly 
decreased progression-free survival compared to stable patients (Figure 9B). In 
accordance, patients with the progressive CTCL subtypes FMF and SS showed 
significantly increased numbers of mast cells compared to MF patients (Figure 
9A) and a decreased progression-free survival (Figure 9B). Similarly, dividing 
CTCL patients into clinically relevant groups exhibiting eczema (mild), plaque 
(moderate) or tumor (moderate/severe) stages or Sézary syndrome (SS, 
severe), a significant increase in mast cell numbers was observed correlating 
with the malignancy of CTCL (Figure 9A). CTCL malignancy was also 
associated with decreased progression-free survival (Figure 9B). Furthermore, 
when CTCL patients with MF, FMF and SS were subdivided according to the 
ISCL/EORTC classification, into groups with stable or progressive disease and 
into groups with <100 mast cells/mm2 or >100 mast cells/mm2, the patients with 
more advanced stages of the disease (IIB-IVA), with progressive disease and 
with >100 mast cells/mm2 showed a significantly shorter progression-free 
survival (Figure 9C). Together, these results show that mast cell numbers 
correlate with progression of CTCL. 
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Figure 9. Mast cell numbers correlate with progression of PCL. (A) The number of tryptase-
positive mast cells was analyzed by microscopic counting of 5 high power fields at 200x 
magnification in skin biopsies from CTCL patients with MF, FMF and SS grouped according to 
ISCL/EORTC classification (IA, n=13; IB, n=8; IIA, n=1; IIB, n=4; IIIB, n=2; IVA, n=1), into 
patients with stable (n=21) and progressive (n=8) disease, into patients with MF (n=23), FMF 
(n=3) and SS (n=3) and into patients with different clinical stages (Eczema, n=13; Plaque, n=10; 
Tumor, n=3; SS, n=3). Data represent the mean ± SEM. Statistical significance was assessed 
by two-tailed Student´s t-test. (B) Progression-free survival, defined as duration (years, months) 
from initial diagnosis until first change of treatment due to disease progression, was determined 
for each group of patients. Data represent the mean ± SEM. Statistical significance was 
assessed by two-tailed Student´s t-test. (C) Kaplan-Meier curves were generated for CTCL 
patients with MF, FMF and SS grouped according to the ISCL/EORTC classification, into stable 
and progressive disease, and into <100 mast cells/mm
2
 and >100 mast cells/mm
2
. Additionally, 
patients with MF and FMF were grouped into those with <100 mast cells/mm
2
 and >100 mast 
cells/mm
2 
(lower right panel). Statistical significance was assessed by Log-rank test. 
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4.1.4. Mast cell degranulation is increased in  
primary cutaneous lymphoma 
Evaluating mast cell numbers in the different skin sections, we noted at higher 
magnifications that most mast cells in PCL sections were degranulated, 
whereas mast cells in normal skin were usually not degranulated. We therefore 
classified mast cells into 3 groups of not degranulated (Figure 10A), moderately 
degranulated (Figure 10B) or extensively degranulated (Figure 10C) mast 
cells34 and determined the percentage of each group in all patients and controls.  
 
A         B 
 
 
 
 
 
 
 
 
 
C 
 
 
 
 
 
 
 
 
Patients with PCL showed a significant increase of extensively degranulated 
mast cells compared to normal skin and inflammatory cutaneous diseases 
(Figure 11A; 26.4 ± 1.9% extensively degranulated (ED) mast cells in PCL (All), 
5.6 ± 0.9% extensively degranulated mast cells in normal skin (Ctrl), 17.0 ± 
1.2% extensively degranulated mast cells in inflammatory cutaneous diseases 
(All), mean ± SEM). CTCL and CBCL patients showed a similar increase in 
extensively degranulated mast cells (Figure 11A). When we compared stable 
(CTCL, n=25; CBCL, n=7) and progressive (CTCL, n=10; CBCL, n=1) patients, 
progressive patients showed significantly more extensively degranulated (ED) 
mast cells and significantly fewer not degranulated (ND) mast cells (Figure 
11B). Thus, in addition to the number of mast cells, the degranulation of mast 
Figure 10. Mast cell degranulation stages. 
Degranulation of mast cells stained with anti-
tryptase antibody (brown), magnification 
1000x. (A) Not degranulated (ND) mast 
cells. (B) Moderately degranulated (MD) 
mast cells. (C) Extensively degranulated 
(ED) mast cells. 
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B 
cells is increased in CTCL and CBCL, and this is particularly prominent in 
progressive forms. Interestingly, we also noted that areas with degranulated 
mast cells were often associated with increased numbers of eosinophils (Figure 
11C). 
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Figure 11. Mast cell degranulation is 
increased in PCL. Degranulation of mast cells 
stained with anti-tryptase antibody was 
evaluated semiquantitatively at 200x 
magnification in skin biopsies from PCL 
patients, patients with inflammatory cutaneous 
diseases and control subjects. (A) Extensively 
degranulated (ED) mast cells were counted in 3 
high power fields at 200x magnification in skin 
biopsies from patients with PCL (All; n=43) 
subdivided into patients with CTCL (n=35) and 
CBCL (n=8), from subjects with normal skin 
(Ctrl; n=12) and from patients with inflammatory 
cutaneous diseases (All; n=24) such as 
psoriasis (n=8), atopic dermatitis (AD; n=8) and 
pseudolymphoma (Pseudolym; n=8). Results 
are presented as percentage of ED mast cells 
of all mast cells and expressed as mean ± 
SEM. Statistical significance was assessed by 
two-tailed Student´s t-test. (B) Not degranulated 
(ND) mast cells and ED mast cells were 
counted in skin biopsies from patients with 
stable PCL (n=32) and progressive PCL (n=11). 
Data represent the mean ± SEM. Statistical 
significance was assessed by two-tailed 
Student´s t-test. (C) Skin biopsies of PCL 
patients were evaluated by H&E staining and 
screened for numbers of eosinophils (dark red 
staining). Progressive PCL, magnification 400x. 
 
C 
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4.1.5. Microvessel density is increased in mycosis fungoides 
To explore possible effects of mast cell infiltration, we determined microvessel 
density in MF patients (n=23) subdivided into eczema (n=13), plaque (n=8) and 
tumor stages (n=2) and in patients with inflammatory cutaneous diseases 
(n=24) (Figure 12, Figure 13). Skin sections were stained with anti-CD31 
antibody and the number of CD31-positive microvessels was counted 
microscopically. For comparison, sections were also stained with anti-CD34 
antibody. Determining the number of CD34-positive cells revealed similar 
results.  
Microvessel density was significantly increased in MF patients compared to 
inflammatory cutaneous diseases (Figure 12A; 26.4 ± 2.1% microvessel 
density/mm2 in MF patients (All), 14.4 ± 0.9% microvessel density/mm2 in 
inflammatory cutaneous diseases (All), mean ± SEM). Comparing the different 
MF stages, we found a significantly increased microvessel density in tumor 
compared to eczema stage (37.2 ± 7.8% microvessel density/mm2 in tumor, 
23.0 ± 1.6% microvessel density/mm2 in eczema stage, mean ± SEM). 
Additionally, when we performed correlation analysis, we observed a highly 
significant correlation between microvessel density and mast cell numbers in 
MF patients (Figure 12B; Spearman r=0.89, p<0.0001). 
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Figure 12. Microvessel density is increased in MF. (A) Skin biopsies from MF patients and 
patients with inflammatory cutaneous diseases were stained with anti-CD31 antibody. 
Microvessel density per mm
2 
was analyzed by microscopic counting of 5 high power fields at 
100x magnification. Data represent the mean ± SEM. Statistical significance was assessed by 
two-tailed Student´s t-test. (B) Microvessel density per mm
2
 (y-axis) positively correlates with 
mast cell number per mm
2
 (x-axis) in MF patients (n=23; Spearman r=0.8855; p<0.0001). 
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Figure 13. Histological analyses showed that microvessel density is increased in MF. (A) 
MF, eczema stage, magnification 200x. (B) MF, plaque stage, magnification 200x. (C) MF, 
tumor stage, magnification 50x. (D) Psoriasis, magnification 150x. (E) Atopic dermatitis, 
magnification 150x. (F) Pseudolymphoma, magnification 150x, staining of microvessels with 
anti-CD31 antibody (brown). 
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4.1.6. Mast cells release mediators that promote tumor growth 
To explore the mechanisms by which mast cells may promote tumor growth, we 
used cytometric bead array (CBA) analysis to measure multiple inflammatory 
cytokines and chemokines (IL-2, IL-4, IL-6, IL-10, IL-17A, TNF, IFN-γ, CXCL8, 
CCL5, CXCL9, CCL2, CXCL10, VEGF, basic FGF and TGF-β1) in the 
supernatant of the human mast cell line HMC1. At baseline, HMC1 cells mainly 
produced IL-6, TGF-β1, VEGF, CCL2 and CXCL8 (Figure 14). All these 
cytokines were induced by treatment with calcium ionophore and inhibited by 
cromolyn. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Mast cells release mediators that promote tumor growth. 1x10
6
 HMC1 cells 
were treated with medium, calcium ionophore A23187 (Ca I) or cromolyn for 30 minutes at 
37°C, washed and incubated in medium for 6 h. Mast cell products IL-6, TGF-β1, VEGF, CCL2 
and CXCL8 were measured in the supernatants using a flow cytometric bead array (CBA). 
Mean data of 4 separate experiments (n=4) are presented as mean ± SD. Statistical 
significance was assessed by two-tailed Student´s t-test. When error bars are not shown, they 
were too small to be diagrammed. 
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4.1.7. Unstimulated PCL cells produce proinflammatory cytokines 
As mast cell infiltration and degranulation within the microenvironment of PCL 
suggested a tumor-promoting role of mast cells, we next sought to investigate 
whether mast cells are able to induce release of cytokines from PCL cells in 
vitro. Initially, we measured multiple inflammatory cytokines (IL-2, IL-4, IL-6, IL-
10, IL-17A, TNF and IFN-γ) in the supernatant of unstimulated primary Sézary 
cells, derived from a patient with Sézary syndrome, and in the supernatant of 
different CTCL cell lines, namely the human CTCL cell line MyLa, derived from 
a patient with MF85, Mac2B, originally derived from a patient with 
CD30+ALCL84, and SeAx, derived from a patient with SS86 by CBA analysis 
(Figure 15). At baseline, Sézary cells and the CTCL cell lines SeAx, Mac2B and 
partly also MyLa produced high levels of TNF. Furthermore, Mac2B and SeAx 
produced also IL-6, exceeding levels produced by primary T-cells derived from 
healthy subjects or by the control cell line Jurkat (Figure 15). Moreover, MyLa 
and SeAx cells and partly also primary Sézary cells were found to release IL-
17A, confirming and extending previous reports on production of IL-17A by 
CTCL cells.73,74 The human B-cell lymphoma cell line BJAB produced mainly IL-
10. 
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Figure 15. Unstimulated PCL cells produce proinflammatory cytokines. Four week-old 
primary T-cells, Jurkat cells, CTCL cell lines Mac2B, MyLa and SeAx, primary Sezary cells and 
human B-cell lymphoma cell line BJAB were cultured for 1 week in medium and the cytokines 
TNF, IL-6, IL-10 and IL-17A were measured in the supernatant of 2x10
6 
cells/ml each using a 
flow cytometric bead array (CBA). Mean data of 4 separate experiments (n=4) are presented as 
mean ± SD. When error bars and bars are not shown, they were too small to be diagrammed. 
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4.1.8. Mast cell supernatant induces changes in cytokine production  
of primary cutaneous lymphoma cells 
When we incubated the PCL cell lines Mac2B and SeAx with supernatant of 
HMC1 cells, we observed a significantly increased production of IL-6 mRNA 
and protein (Figure 16A) as well as a significantly decreased production of TGF-
β1 mRNA and protein (Figure 16B) in Mac2B cells and SeAx cells. Secretion of 
IL-2, IL-4, IL-10, IL-17A, TNF and IFN-γ, as well as CXCL8, CCL5, CXCL9, 
CCL2 and CXCL10 was not altered. Together, these results demonstrate that 
mast cells can induce changes in cytokine production of CTCL cells in vitro.  
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Figure 16. Mast cell supernatant induces changes in cytokine production of PCL cells. 
Mac2B and SeAx cells were cultured with or without supernatant of HMC1 cells for 24 h, 
washed and incubated in medium for 6 h. IL-6 (A) and TGF-β1 (B) mRNA levels relative to 
GAPDH expression were determined using quantitative real-time PCR. Statistical significance 
was assessed by two-tailed Student´s t-test. Mac2B and SeAx cells were cultured with or 
without supernatant of HMC1 cells for 48 h, washed and incubated in medium for 48 h. Levels 
of IL-6 (A) and TGF-β1 (B) were measured in the supernatant of 5x10
5 
cells/ml using CBA. 
Statistical significance was assessed by two-tailed Student´s t-test (ns, not significant). Mean 
data of 4 separate experiments (n=4) are presented as mean ± SD. 
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4.1.9. Mast cell supernatant induces proliferation  
of primary cutaneous lymphoma cells  
To test whether addition of mast cell supernatant also affects proliferation of 
PCL cells, primary Sézary cells, the CTCL cell lines MyLa, Mac2B and SeAx, as 
well as primary T-cells, Jurkat cells and the B-cell lymphoma cell line BJAB 
were incubated with supernatant of HMC1 cells and proliferation was measured 
for 80 h in 4 hour intervals using the Cell Titer 96® AQueous One Solution Assay 
(Figure 17). Briefly, 100 µl cells and 20 µl MTS (3-(4,5-dimethyl-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) were added per well 
in a 96-well plate and incubated for 1 h at 37°C and 5% CO2. Absorbance of 
formazan, which is converted from living cells by MTS, was measured at 490 
nm in an ELISA reader. We observed that mast cell supernatant significantly 
increased proliferation of Sézary cells and all CTCL cell lines. This increase was 
often comparable to stimulation with a cocktail of several cytokines used as 
positive control. When we inhibited mediator release by pretreatment of HMC1 
cells with cromolyn, mast cell supernatant failed to affect proliferation of the 
CTCL cell lines Mac2B and SeAx (Figure 17, lower right panels). In contrast to 
the increased proliferation of PCL cells, primary T-cells and Jurkat cells only 
showed a limited response to mast cell supernatant (Figure 17, upper panels). 
Within the first 32 hours, we observed a typical growth curve with an 
exponential growth starting at 24 hours of incubation, which decreased after 
around 48 hours. When we added new media or mast cell supernatant after 48 
hours, this had only little effect on CTCL cells alone, but, surprisingly, led to a 
highly increased cell number when mast cell supernatant or cytokine cocktail 
were added. This effect was most prominent in SeAx cells and primary Sézary 
cells. In summary, these results demonstrate that mast cells can induce 
proliferation of CTCL cells in vitro. CTCL cells might be more sensitive to mast 
cell stimulation than primary T-cells. 
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Figure 17. Mast cell supernatant induces proliferation of PCL cells. Primary T-cells, Jurkat 
cells, primary Sézary cells, the CTCL cell lines SeAx, Mac2B and MyLa as well as the human B-
cell lymphoma cell line BJAB were cultured with (HMC1 supernatant) or without (Control) 
supernatant of HMC1 cells or with a cocktail of several cytokines (IL cocktail; IL-1α, IL-1β, IL-2, 
IL-4 and IL-7). SeAx cells and Mac2B cells were additionally cultured with mast cell supernatant 
of HMC1 cells, which were pretreated with cromolyn (Cromolyn). Proliferation was measured for 
80 h using the Cell Titer 96® AQueous One Solution Assay. Data represent the mean ± SD of 4 
separate experiments (n=4). When error bars are not shown, they were too small to be 
diagrammed. Statistical significance was assessed by two-tailed Student´s t-test (ns, not 
significant). 
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4.2. Mast cells in the microenvironment of murine tumors 
4.2.1. Murine mast cell supernatant induces cytokine release and 
proliferation of the mouse T-cell lymphoma cell line EL4 
To transfer the in vitro data obtained with human PCL cells and cell lines to an 
in vivo system, we established a murine lymphoma model injecting 
subcutaneously the mouse T-cell lymphoma cell line EL4 into the flanks of mast 
cell-deficient mice and controls. To also investigate cytokine production and 
proliferation of EL4 cells upon stimulation with mast cells, release of cytokines 
(IL-2, IL-4, IL-6, IL-10, IL-17A, TNF and IFN-γ) was measured by CBA (Figure 
18). EL4 cells were found to express a proinflammatory cytokine pattern at 
baseline (Figure 18A), similar to human PCL cells. Stimulation of EL4 cells with 
supernatant of murine bone marrow-derived mast cells (BMMC) induced 
significant upregulation of TNF, IL-6 and IL-17A (Figure 18B). In addition, 
supernatant of BMMCs significantly increased proliferation of EL4 cells (Figure 
18C). 
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Figure 18. Murine mast cell supernatant induces cytokine release and proliferation of 
mouse T-cell lymphoma cell line EL4. (A) EL4 cells and murine bone marrow-derived mast 
cells (BMMC) were cultured for 1 week and the cytokines TNF, IL-6, IL-10 and IL-17A were 
measured in the supernatant of 2x10
6
 cells/ml using a flow cytometric bead array (CBA). Mean 
data of 4 separate experiments (n=4) are presented as mean ± SD. (B) EL4 cells were cultured 
with or without supernatant of BMMC for 48 h, washed and incubated in medium for 48 h. 
Levels of TNF, IL-6 and IL-17A were measured in the supernatant of 5x10
5
 cells/ml using CBA. 
Statistical significance was assessed by two-tailed Student´s t-test. Mean data of 4 separate 
experiments (n=4) are presented as mean ± SD. (C) EL4 cells were cultured with (BMMC 
supernatant) or without (Control) supernatant of BMMC or with a cocktail of several cytokines 
(IL cocktail; IL-1α, IL-1β, IL-2, IL-4 and IL-7) and proliferation was measured for 80 h using Cell 
Titer 96® AQueous One Solution Assay. Data represent the mean ± SD of 4 separate 
experiments (n=4). When error bars are not shown, they were too small to be diagrammed. 
Statistical significance was assessed by two-tailed Student´s t-test (ns, not significant). 
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4.2.2. Mast cell-deficient mouse models for the 
investigation of tumor growth 
To analyze the functional role of mast cells in vivo, we evaluated tumor growth 
in our recently developed mouse model that allows inducible selective depletion 
of connective tissue mast cells (Figure 19).33,34 Breeding the mast cell-specific 
transgenic line Mcpt5-Cre (Figure 19A, right) to the iDTR line (Figure 19A, 
left)35, we generated Mcpt5-Cre+/iDTR+ mice that show efficient and specific 
depletion of cutaneous and peritoneal mast cells upon i.p. injections with 
diphtheria toxin (Figure 19B, C).  
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Figure 19. Mouse model of inducible mast cell deficiency. (A) Genotyping of iDTR (left) and 
Mcpt5-Cre (right) mice by PCR. The 242 bp fragment represents the iDTR gene, whereas the 
603 bp fragment shows the wild type allele. For Mcpt5-Cre, the 554 bp fragment indicates the 
presence of the gene encoding the Cre recombinase (Cre+). The 224 bp fragment indicates the 
wild type (Cre-) allele. (B) Mcpt5-Cre-/iDTR+ skin biopsy before (left) and after (right) i.p. DT 
injections, magnification 100x. (C) Mcpt5-Cre+/iDTR+ skin biopsy before (left) and after (right) 
i.p. DT injections, magnification 100x. Giemsa staining, mast cells are marked by black arrows. 
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To exclude that multiple DT injections may influence tumor growth, we 
additionally used a mouse model of constitutive mast cell deficiency. Crossing 
Mcpt5-Cre animals to the R-DTA line36 also showed, in double positive 
littermates (Figure 19A, right; Figure 20A), depletion of connective tissue mast 
cells (Figure 20B).  
A                                        
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Figure 20. Mouse model of constitutive mast cell deficiency. (A) Genotyping of R-DTA mice 
by PCR. The 592 bp fragment represents the R-DTA gene. (B) Mcpt5-Cre-/R-DTA+ (left) and 
Mcpt5-Cre+/iDTR+ (right) skin biopsy, magnification 100x. Giemsa staining, mast cells are 
marked by black arrows. 
 
 
Furthermore, to analyze the role of mast cells in tumor neoangiogenesis, we 
used Mcpt5-Cre+/VEGFfl/fl mice that lack mast cell-derived VEGF. For 
comparison, we also analyzed tumor growth in the traditionally used mast cell-
deficient C57BL/6 KitW-sh/W-sh line, which shows several other defects in addition 
to the deficiency of mast cells due to a genetic conversion in the Kit gene 
promoter30,32, and in WT C57BL/6 controls. 
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4.2.3. Mast cell-deficient mice show decreased growth of 
subcutaneously injected tumors 
In analogy to a recently published mouse model of CTCL79, we injected the 
mouse T-cell lymphoma cell line EL4 subcutaneously in Mcpt5-Cre+/iDTR+, 
Mcpt5-Cre+/R-DTA+, Mcpt5-Cre+/VEGFfl/fl, C57BL/6 KitW-sh/W-sh and the 
appropriate control mice. Tumor volume (right) and area (left) were significantly 
decreased in the mast cell-deficient Mcpt5-Cre+/iDTR+ and C57BL/6 KitW-sh/W-sh 
mice compared to the Mcpt5-Cre-/iDTR+ and WT C57BL/6 controls (Figure 
21A, upper panels). Subcutaneous injection of two other tumor cell lines, the 
pancreatic cancer cell line Pan02 (Figure 21B) and the Lewis lung carcinoma 
cell line LLC (Figure 21C), showed similar results. Comparing Mcpt5-Cre+/R-
DTA+ and their controls, the difference was not as obvious, which may be due 
to possible additional effects of R-DTA (Figure 21A, lower panels). Depleting 
mast cell-derived VEGF slightly decreased tumor volume and tumor area (not 
significant), but not to the same level as in the mast cell-deficient animals. 
These data suggest that mast cell-derived VEGF may participate in tumor 
growth, but other mediators may play more significant roles. On the other hand, 
the lack of mast cell-derived VEGF may also be compensated for by other 
factors.  
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Figure 21. Mast cell-deficient mice show decreased growth of subcutaneously injected 
tumors. (A) 1x10
6 
cells of the murine T-cell lymphoma cell line EL4 were injected s.c. into the 
flanks of mast cell-deficient Mcpt5-Cre+/iDTR+ (upper panels) or Mcpt5-Cre+/R-DTA+ (lower 
panels) and C57BL/6 Kit
W-sh/W-sh
 mice and Mcpt5-Cre-/iDTR+ (upper panels) or Mcpt5-Cre-/R-
DTA+ (lower panels) and WT C57BL/6 control mice as well as Mcpt5-Cre+/VEGF
fl/fl 
mice and 
tumor area (left) and tumor volume (right) were assessed for 14 days using a Mitutoyo Quick 
Mini caliper. Data represent the mean ± SD of 4-6 tumors (n=4, C57BL/6 Kit
W-sh/W-sh
 and WT 
C57BL/6 mice; n=6, Mcpt5-Cre+/iDTR+, Mcpt5-Cre-/iDTR+, Mcpt5-Cre+/R-DTA+, Mcpt5-Cre-
/R-DTA+ and Mcpt5-Cre+/VEGF
fl/fl
). When error bars are not shown, they were too small to be 
diagrammed. Statistical significance was assessed by two-tailed Student´s t-test. (B) 1x10
6 
cells 
of the murine cell line Pan02 were injected s.c. into the flanks of mast cell-deficient Mcpt5-
Cre+/iDTR+ and C57BL/6 Kit
W-sh/W-sh
 mice as well as Mcpt5-Cre-/iDTR+ and WT C57BL/6 
control mice and (left) tumor area (left) and tumor volume (right) were assessed for 28 days 
using a Mitutoyo Quick Mini caliper. Data represent the mean ± SD of 4-6 tumors (n=4, C57BL/6 
Kit
W-sh/W-sh
 and WT C57BL/6 mice; n=6, Mcpt5-Cre+/iDTR+ and Mcpt5-Cre-/iDTR+). When error 
bars are not shown, they were too small to be diagrammed. Statistical significance was 
assessed by two-tailed Student´s t-test. (C) 1x10
6 
cells of the murine cell line LLC were injected 
s.c. into the flanks of mast cell-deficient Mcpt5-Cre+/iDTR+ and C57BL/6 Kit
W-sh/W-sh
 mice as 
well as Mcpt5-Cre-/iDTR+ and WT C57BL/6 control mice and tumor area (left) and tumor 
volume (right) were assessed for 18 days using a Mitutoyo Quick Mini caliper. Data represent 
the mean ± SD of 4-6 tumors (n=4, C57BL/6 Kit
W-sh/W-sh
 and WT C57BL/6 mice; n=6, Mcpt5-
Cre+/iDTR+ and Mcpt5-Cre-/iDTR+). When error bars are not shown, they were too small to be 
diagrammed. Statistical significance was assessed by two-tailed Student´s t-test. 
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Histologically, EL4 tumors in WT C57BL/6 (Figure 22A) and Mcpt5-Cre-/iDTR+ 
(Figure 22B) controls were characterized by marked accumulation of mast cells 
along the tumor rim, similar to the mast cell infiltration in human CTCL (Figure 
8B, C). In contrast, a smaller tumor infiltrate and only few mast cells were found 
in mast cell-deficient Mcpt5-Cre+/iDTR+ mice (Figure 22C). To also analyze 
microvessel density in EL4 tumors in analogy to MF patients, we stained tumor 
tissue with anti-CD31 antibody and observed, as expected, a decreased 
microvessel density in Mcpt5-Cre+/iDTR+ mice (Figure 22F) compared to WT 
C57BL/6 (Figure 22D) and Mcpt5-Cre-/iDTR+ controls (Figure 22E). 
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Figure 22. Mast cell-deficient mice show decreased growth of subcutaneously injected 
tumors and decreased microvessel density. (A) WT C57BL/6, skin biopsy of EL4 tumor at 
day 14, magnification 100x. (B) Mcpt5-Cre-/iDTR+, EL4 tumor, magnification 100x. (C) Mcpt5-
Cre+/iDTR+, EL4 tumor, magnification 100x. Toluidine blue staining, mast cells (dark blue). 
Inserts show mast cells at 400x magnification. (D) WT C57BL/6 (E) Mcpt5-Cre-/iDTR+ (F) 
Mcpt5-Cre+/iDTR+, skin biopsy of EL4 tumor at day 14, magnification 100x, CD31 staining. 
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4.2.4. Mast cell-deficient mice show decreased  
chemically induced carcinogenesis 
Besides subcutaneous injection of tumor cell lines, we also performed the well-
established two-step skin carcinogenesis model, where animals are treated with 
a single DMBA application followed by multiple TPA treatments. We observed 
decreased mast cell numbers and a reduced number of papillomas in mast cell-
deficient Mcpt5-Cre+/iDTR+ and C57BL/6 KitW-sh/W-sh mice (Figure 23). In 
Mcpt5-Cre+/iDTR+ animals, we were not able, after several weeks, to keep 
mast cells away from the developing papillomas by additional subcutaneous DT 
injections. The increase in papilloma number (Figure 23B) followed the increase 
in the number of mast cells (Figure 23A). Histologically, WT C57BL/6 (Figure 
24A) and Mcpt5-Cre-/iDTR+ (Figure 24C) controls showed accumulation of 
mast cells directly under the papilloma area (right panel), whereas in Mcpt5-
Cre+/iDTR+ (Figure 24D) and C57BL/6 KitW-sh/W-sh (Figure 24B) mice, only few 
mast cells were detectable. All animals showed a thickened epidermis. 
Together, these results show that mast cells also promote chemically induced 
carcinogenesis. 
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Figure 23. Mast cell-deficient mice show decreased chemically induced carcinogenesis. 
Mast cell-deficient Mcpt5-Cre+/iDTR+ and C57BL/6 Kit
W-sh/W-sh
 mice and Mcpt5-Cre-/iDTR+ and 
WT C57BL/6 control mice were treated with DMBA/TPA. (A) Skin biopsies were stained at 
different time points by Giemsa staining and number of mast cells was analyzed by microscopic 
counting of 5 high power fields at 200x magnification and calculating the mean number of mast 
cells per mm
2
. Data represent the mean ± SD. Statistical significance was assessed by two-
tailed Student´s t-test. (B) Papillomas were counted macroscopically at different time points. 
Due to the low number of mice at later time points, statistical significance could not be assessed 
for this experiment. 
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Figure 24. Histological analyses revealed that mast cell-deficient mice show decreased 
chemically induced carcinogenesis. (A) WT C57BL/6 skin biopsy, before (left, magnification 
100x) and after (right, magnification 50x) DMBA/TPA treatment. (B) C57BL/6 Kit
W-sh/W-sh
 skin 
biopsy, before (left, magnification 100x) and after (right, magnification 50x) DMBA/TPA 
treatment. (C) Mcpt5-Cre-/iDTR+ skin biopsy, before (left, magnification 100x) and after (right, 
magnification 50x) DMBA/TPA treatment. (D) Mcpt5-Cre+/iDTR+ skin biopsy, before (left, 
magnification 100x) and after (right, magnification 50x) DMBA/TPA treatment. Giemsa staining, 
mast cells are marked by black arrows. 
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5. Discussion 
 
5.1. Increased mast cell number and microvessel density in 
primary cutaneous lymphoma 
Mast cell numbers are increased in many cancers.44-55 However, the functional 
role of mast cells in cancers is not well defined. Recent studies demonstrated 
that mast cells are probably not only innocent bystanders, but actively 
participate in modulating tumor growth.41-43,59,60 They have been shown to exert 
relevant pro-44-51 and antitumorigenic52-54 effects. In the present study, we report 
for the first time on a protumorigenic role of mast cells in primary cutaneous 
lymphoma. The number of mast cells in skin sections of CTCL and CBCL 
patients is highly increased compared to normal skin and inflammatory 
cutaneous diseases. Mast cell infiltration is most prominent in the periphery of 
CTCL, especially at the rims of the infiltrate. 
Our data on mast cell numbers in normal skin (Figure 7A) are in agreement with 
several recent studies, which also reported on an average of 40 mast 
cells/mm2.95-97 In these studies, no differences in skin mast cell numbers or 
distribution have been described when comparing skin obtained from male or 
female, and from young or old individuals.95 However, mast cell numbers were 
found to vary to some degree between different sites of the body. The highest 
numbers of mast cells were observed in the most superficial skin layers and at 
peripheral skin sites, like chin and nose.95 To exclude variability in mast cell 
numbers in our study, we analyzed skin biopsies from comparable sites and 
layers of the body. Furthermore, we included an appropriate number of control 
subjects reflecting similar sampling locations. There are also few reports on 
higher mast cell numbers in normal skin98,99, which may correspond to different 
fixation, staining or counting methods.96 In addition, there are several studies on 
the number and activation of mast cells in urticaria, psoriasis and atopic 
dermatitis.100-118 Here, numbers of mast cells were increased to levels well 
comparable to the mast cell counts that we observed in inflammatory cutaneous 
diseases (Figure 7A). Thus, we believe our method of staining and counting 
mast cells results in reliable data. With this method, we observed for the first 
time highly increased numbers of mast cells in PCL, which even exceed the 
mast cell counts in inflammatory cutaneous diseases. 
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Our observation that mast cell numbers correlate with disease progression in 
CTCL (Figure 7C, Figure 9) is of potential significance for clinical management 
of patients with CTCL. Possibly, mast cell infiltration could serve as additional 
diagnostic criterion, as prognostic parameter or as follow-up marker. To 
definitively clarify whether mast cell counts are useful as diagnostic or 
prognostic marker in CTCL, however, further studies, especially prospective 
studies, with sufficient number of patients and statistical power are necessary.  
Our data also support a rationale for therapeutic inhibition of mast cells, e.g. by 
antihistamines, cromolyn or, in the near future, by targeted drugs, which is 
predicted to decrease growth of PCLs or even lead to regression of the disease. 
The concept of inhibiting tumor progression by antihistamines has been studied, 
to some extent, in various cancer models.119-122 For example, antihistamines 
have been found to inhibit growth of xenograft colon carcinomas and 
melanomas in mice and to delay proliferation of several human colon carcinoma 
cell lines.119,120 In breast cancer, treatment with H2-receptor antagonists resulted 
in complete remission of 70% of experimentally induced tumors.121 However, in 
clinical trials, H2-receptor antagonists showed only limited success in treatment 
of breast and colon cancer.122 In murine xenograft models of prostate 
adenocarcinoma44 and thyroid cancer45, treatment with cromolyn, known to 
inhibit degranulation of mast cells and release of inflammatory cytokines, 
blocked growth of tumors, supporting our observation that mast cell supernatant 
of cromolyn-treated mast cells is not able to induce proliferation of tumor cells in 
vitro (Figure 17). Since patients with CTCL often suffer from pruritus, particularly 
those with MF and SS, antihistamines are already administered to many CTCL 
patients. However, no studies exist until now that compare the development of 
CTCL in the presence or absence of antihistamines. 
In addition, an increasing number of studies in different types of tumors 
demonstrate that the tumor microenvironment interacts with tumor cells in a 
complex manner and crucially influences tumor growth.37,61,123 For instance, in 
H&E-stained sections of our 43 patients with CTCL and CBCL, we also 
observed increased numbers of eosinophils associated with mast cell infiltration 
(Figure 11C). Similarly, in Hodgkin´s lymphoma, aggregation of eosinophils 
together with mast cells has been described.62 Several studies have also 
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demonstrated that mast cell-derived mediators play important roles in eosinophil 
chemotaxis, activation and function.124-127  
Besides the interaction with other cell types of the tumor microenvironment, 
mast cells can also influence structural components in the tumor surrounding. 
For example, in lung cancer63 and squamous cell carcinomas of the 
esophagus64 and cervix65, mast cell infiltrates have been correlated with both 
microvessel density and tumor progression, comparable to our results (Figure 
12). In agreement, Karpova et al128 reported on increased blood vessel density 
and lymphangiogenesis in patients with Sézary syndrome. This observation was 
also confirmed by Mazur et al, who reported on significantly increased CD34-
positive microvessels in MF compared to normal skin.129 Similarly, an elevated 
number of CD31-positive vessels has been described in cutaneous B-cell 
lymphomas.130 
 
5.2. Stimulation of tumor growth by mast cells in vitro and in vivo 
We also report for the first time on a functional role of mast cells in cutaneous 
lymphoma performing in vitro and in vivo experiments. In vitro, mast cell 
supernatant is able to induce changes in cytokine production and proliferation of 
malignant cells (Figure 16 – Figure 18).  
In addition, mast cell products can influence other immune cells. As mentioned 
above, studies from different laboratories demonstrated that mast cell-derived 
mediators are pivotal in eosinophil maturation and chemotaxis.124-127 Among the 
mast cell products that affect eosinophils are cytokines, such as IL-1, IL-3, IL-4, 
IL-5, IL-13, TNF and GM-CSF, and chemokines, including CXCL8 (IL-8), CCL5 
(RANTES) and CCL2 (MCP-1).127 As shown in Figure 14, we were able to 
detect high levels of CCL2 and CXCL8 in supernatants of the human mast cell 
line HMC1. Comparably, in lesional biopsies of basal cell carcinoma, tryptase-
positive mast cells have been shown to express CXCL8 (IL-8) and CCL5 
(RANTES).131 Furthermore, human lung mast cells activated with SCF and anti-
IgE have been found to express CCL2 (MCP-1).132 Whereas human mast cell 
lines activated by dengue virus secreted CCL5 (RANTES) and MIP-1, but not 
CXCL8 (IL-8)133, similarly activated cord blood-derived mast cells expressed 
CCL5 (RANTES).133  
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5.2.1. Potential effects of mast cells on different hallmarks of cancer 
Inflammation plays an important role in different stages of tumor development, 
including initiation, promotion, malignant conversion, invasion and 
metastasis.134 Here, tumor-infiltrating immune cells are known to participate in 
an extensive and dynamic crosstalk with cancer cells.134 Several basic concepts 
linking inflammation and cancer have now been developed, for example the 
concept that chronic inflammation as well as "undetectable" inflammation, e.g. 
obesity-induced inflammation, increase cancer risk.134 Moreover, it is well 
known that different types of immune cells are usually present within tumors 
and affect cancer cells through the production of cytokines, chemokines, growth 
factors, prostaglandins, reactive oxygen and nitrogen species. In developing 
tumors, antitumorigenic and protumorigenic immune mechanism often coexist, 
however, if the tumor is not rejected, the protumorigenic effect increasingly 
dominates.134 The immune cells that infiltrate the tumor microenvironment 
include innate immune cells, such as macrophages, neutrophils, mast cells, 
myeloid-derived suppressor cells, dendritic cells and natural killer cells, and 
adaptive immune cells, like T and B lymphocytes. Although investigations on 
the role of mast cells in tumors are still at the very beginning, mast cells have 
been demonstrated to actively participate in several hallmarks of cancer, 
described below.37,123  
Recent studies demonstrated that mast cells can exert mitogenic, 
proangiogenic and proinvasive functions within the microenvironment of tumors. 
Moreover, they have been reported to recruit other tumor-infiltrating immune 
cells and to suppress the cytotoxic activity of the NK/T-cells. Figure 25 depicts 
the potential participation of mast cells in the scheme of Hanahan and 
Weinberg37 illustrating the different hallmarks of cancer: 
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Figure 25. Potential participation of mast cells in different hallmarks of cancer. Adapted 
from Hanahan and Weinberg, 2011
37
 and Hanahan and Coussens, 2012
123
. Mast cells are 
shown as violet cells. Mast cell mediators are shown in violet, bold violet mediators are the 
mediators that have been identified to participate in PCL in the present study. 
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5.2.1.1. Sustaining proliferative signaling 
Proliferation of cancer cells can be mediated by autocrine production of growth 
factors135 as well as by paracrine mechanisms, whereby surrounding cells 
produce mediators that induce proliferation of cancers.135 Here, mast cells may 
contribute directly or indirectly by release of mediators such as TGF-β, TNF-α, 
FGF, various interleukins, chemokines and histamine.123,136 In the present 
study, we observed that HMC1 cells produced especially high levels of TGF-β1 
and CCL2 (MCP-1) (Figure 14).  
CCL2 primarily recruits tumor-associated macrophages (TAMs).136 TAMs 
accumulate in the microenvironment of tumors, especially in hypoxic areas136-
138, due to HIF-1-dependent upregulation of the chemokine receptor CXCR4139, 
which is also present on mast cells. In response to for example TGF-β, TAMs 
acquire M2 properties, promoting tumor proliferation and progression.136 
Interestingly, a recent study using Hodgkin´s lymphoma cell lines demonstrated 
that mouse mast cells do not affect proliferation of all Hodgkin´s lymphoma cell 
lines, but subcutaneous injection of these cell lines together with mast cells 
gave rise to significantly larger tumors compared to injection of Hodgkin´s 
lymphoma cells alone.140 Furthermore, Mizuno et al140 showed that mast cells 
incubated with the proteasome inhibitor bortezomib released significantly less 
CCL2 than untreated mast cells.  
 
5.2.1.2. Avoiding immune destruction 
Although the immunosuppressive activity of mast cells is not well characterized, 
it is known that they can indirectly regulate immunosuppression by releasing 
cytokines that recruit MDSCs and Tregs.
43 Again, the cytokines CCL2 and TGF-
β1 may play a major role in this process. CCL2 recruits monocytes, memory T 
cells, and dendritic cells to sites of tissue injury, infection and inflammation. 
TGF-β acts on surrounding stromal cells, immune cells, endothelial and smooth-
muscle cells. Thereby, TGF-β promotes immunosuppression and angiogenesis, 
which in turn facilitate invasion of cancers.141 In normal cells and early stages of 
tumorigenesis, TGF-β has been reported to block the cell cycle at the G1 stage, 
leading to inhibition of proliferation, enhanced differentiation or induction of 
apoptosis.142 This might be a reason for the decreased TGF-β production in 
PCL cell lines upon incubation with HMC1 cell supernatant, in the present study 
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(Figure 16), because PCL cells were harvested at early phases of tumor cell 
expansion and mast cell supernatant stimulates them to overcome this early 
phase of minor proliferation. This hypothesis is also supported by the 
proliferation curves, shown in Figure 17, which show that PCL cells start their 
major growth phase after the second addition of mast cell supernatant. Later, in 
older tumor cells, parts of the TGF-β signaling pathway are mutated, and TGF-β 
no longer controls the tumor cells.141 Moreover, the increased IL-6 production in 
PCL cells upon stimulation with HMC1 cell supernatant (Figure 16) promotes 
inflammation and serves as a detrimental signal for the tumor, by inducing 
apoptosis of tumor cells.55  
 
5.2.1.3. Activating invasion and metastasis 
In addition to unlimited proliferation of cancer cells, a large variety of 
coordinated cellular processes control invasion and metastasis.143 For example, 
specific factors stimulate attachment of tumor cells to host extracellular matrix, 
tumor cell-mediated proteolysis of host barriers, migration of tumor cells and 
colony formation of tumor cells in the target organ for metastasis.143 
Mast cells and macrophages are known to produce a series of proteases 
(MMPs) that promote tissue invasion by remodeling structural components of 
the extracellular matrix.123 One of these proteases is MMP-9, which is primarily 
produced by mast cells and causes degradation of the extracellular matrix. 
Recently, mast cell-derived MMP-9 has been demonstrated to promote 
invasiveness of prostate cancer by Pittoni et al.44 Analyzing the role of mast 
cells in transgenic mouse prostate tumors showed that mast cells are essential 
players in the initial stages of prostate tumor progression, by supplying MMP-9 
to the tumor microenvironment.44 MMP-9 is also involved in the mobilization of 
VEGF from the extracellular matrix
144
, supporting the switch from vascular 
quiescence to neoangiogenesis.44 Comparable to our first experiments 
investigating Mcpt5-Cre/VEGFfl/fl mice (Figure 21), one could imagine 
experiments with Mcpt5-Cre/MMP-9fl/fl mice44 to clarify the specific contribution 
of mast cell-derived MMP-9 to tumor neo-angiogenesis and invasiveness. 
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5.2.1.4. Inducing angiogenesis 
Most cancers are associated with the formation of new vessels from existing 
vasculature, which is called tumor-induced sprouting angiogenesis. Whereas 
normal angiogenesis ensures that developing or healing tissues receive an 
adequate supply of nutrients, the availability of nutrients is limited by 
competition among different proliferating cells in tumors. As a result, tumor cells 
induce sprouting of new vessels to secure their nutrient supply. The 
mechanisms by which cancer cells stimulate pathological neovascularization 
closely mimic those utilized by normal cells to foster physiological 
angiogenesis.145 
In this process, the cytokine vascular endothelial growth factor (VEGF) plays a 
prominent role. VEGF is known to increase endothelial cell permeability, to 
stimulate endothelial cell proliferation, to inhibit endothelial cell apoptosis and to 
enhance endothelial cell migration.145 In tumors, VEGF is released by tumor 
cells as well as by cells of the tumor microenvironment, then diffuses through 
the extracellular matrix and finally stimulates endothelial cells lining existing 
vessels in the proximity of the tumor to form new vessel sprouts. In addition to 
VEGF, several other cytokines have been shown to participate in angiogenesis. 
For example, FGF can also stimulate endothelial cell proliferation and enhance 
endothelial cell migration.145 In contrast, TNF-α inhibits endothelial cell 
proliferation.145 TGF-β increases the stability of vessel walls, supports 
anchorage-independent growth of fibroblasts, is chemotactic for monocytes and 
fibroblasts and stimulates angiogenesis in the presence of inflammatory 
responses in vivo.145 PDGF has been shown to induce DNA synthesis in 
endothelial cells and to stimulate proliferation of smooth muscle cells and 
pericytes.145 Furthermore, GM-CSF promotes endothelial cell proliferation and 
migration and Ang-1 induces endothelial cell sprout formation in vitro and 
increases girth and stability of the endothelium.145  
Mediators produced by mast cells, namely VEGF, FGF, TNF-α, TGF-β, PDGF, 
GM-CSF, Ang-1, CXCL8 and prostaglandins, have been demonstrated to 
regulate vascular cell survival, proliferation and motility, along with tissue 
remodeling and new vessel formation.41,146 In the present study, we also 
observed release of high levels of VEGF, TGF-β1 and CXCL8 from human mast 
cells (Figure 14). Further supporting our hypothesis that mast cells participate in 
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neovascularization of PCL, we observed an increased microvessel density 
correlating with mast cell counts (Figure 12). In addition, growth of EL4 tumors 
was delayed to some degree (not significant) in mast cell-specific VEGF 
knockout mice (Figure 21). 
 
5.2.2. Decreased growth of subcutaneously injected tumors and 
decreased chemically induced carcinogenesis in mast cell-deficient mice 
In the present study, we took advantage of a new transgenic mast cell-deficient 
mouse model, the Mcpt5-Cre/iDTR model, focusing for the first time on tumor 
research (Figure 21, Figure 23). To investigate growth of lymphomas in vivo, we 
chose to use subcutaneous injections of the mouse lymphoma cell line EL4, 
which we thought would best mimic cutaneous lymphoma in mice and which 
closely resembles the model of Wu et al (2011)79. Our results show significant 
differences in growth of subcutaneously injected tumors and chemically induced 
papillomas between mast cell-deficient Mcpt5-Cre+/iDTR+ animals and Mcpt5-
Cre-/iDTR+ controls, while both groups received repeated diphtheria toxin 
injections before and during the experiments. These data demonstrate that 
mast cells are a crucial component within the tumor microenvironment able to 
control tumor progression. 
In our experiments, we observed similarly delayed tumor growth in Mcpt5-
Cre+/iDTR+ animals like in C57BL/6 KitW-sh/W-sh mice (Figure 21, Figure 23). 
This observation suggests that the previously reported reduced development of 
various tumors in mast cell-deficient WBBF1-KitW/Wv 147 and C57BL/6 KitW-sh/W-sh 
148 mice is also based on the absence of mast cells and not on the other 
immunological alterations present in these models. In the past, these additional 
defects had led to misinterpretation of results and false attribution of certain 
tasks to mast cells, such as suppression of contact allergy.
34
 Despite the similar 
response of Mcpt5-Cre+/iDTR+ and C57BL/6 KitW-sh/W-sh mice in our 
experiments, we can, however, not exclude that particular effects of mast cells 
on tumor development have to be newly defined in the context of the more 
specific Mcpt5-Cre/iDTR model. 
Investigating the growth of subcutaneously injected tumor cell lines, we were 
only able to follow tumor growth for a limited period of time (Figure 21). After 
maximally 30 days, the tumors were too large and animals had to be sacrificed. 
Discussion 
76 
To exclude possible differences in tumor growth between mast cell-deficient 
mice and controls at later time points, we therefore also used a model of 
chemically induced carcinogenesis, which allowed us to follow papilloma growth 
for 20 weeks (Figure 23). These experiments, however, revealed that the 
Mcpt5-Cre/iDTR model is also associated with certain disadvantages. As Figure 
23 shows, we were not able to sufficiently deplete mast cells for longer time 
periods, not even with additional injections of DT subcutaneously around the 
developing papillomas. After around 15 applications of TPA, at treatment week 
7, mast cell numbers started to increase again and only 1 week later the 
number of papillomas also increased. On the other hand, besides the selective 
depletion of mast cells, an essential advantage of the Mcpt5-Cre model is the 
additional possibility of analyzing mast cell-specific products in tumor growth by 
cross breeding Mcpt5-Cre with different "floxed" lines. 
 
Taken together, we could show that mast cell numbers are significantly 
increased in human primary cutaneous lymphoma. Patients with advanced 
stages of the disease showed higher mast cell counts than stable patients and 
mast cell numbers in different clinical stages correlated with disease 
progression. In vitro, we observed enhanced production of cytokines and 
increased proliferation of PCL cells in response to treatment with mast cell 
supernatant. In vivo, growth of subcutaneously injected tumors and chemically 
induced carcinogenesis was significantly decreased in mast cell-deficient 
transgenic mice. 
To further define the role of mast cells in tumors, systematic analyses of 
different human tumor entities in different tumor stages are recommended. In 
addition, systematic investigations on growth of genetic tumor models in mast 
cell-deficient mice and on interactions of mast cells with tumor cells and other 
immune cells are suggested. Results of these studies may serve to better 
understand the pathogenesis of tumors and to develop more efficient 
treatments for cancer patients. 
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